



This is a repository copy of *Proteasome-dependent protein quality control of the peroxisomal membrane protein Pxa1p*.

White Rose Research Online URL for this paper:  
<https://eprints.whiterose.ac.uk/160997/>

Version: Published Version

---

**Article:**

Devarajan, S., Meurer, M., van Roermund, C.W.T. et al. (5 more authors) (2020) Proteasome-dependent protein quality control of the peroxisomal membrane protein Pxa1p. *Biochimica et Biophysica Acta (BBA) - Biomembranes*, 1862 (9). 183342. ISSN 0005-2736

<https://doi.org/10.1016/j.bbamem.2020.183342>

---

© 2020 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:  
<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

Proteasome-dependent protein quality control of the peroxisomal membrane protein Pxa1p

S. Devarajan, M. Meurer, C.W.T. van Roermund, X. Chen, E.H. Hetteema, S. Kemp, M. Knop, C. Williams



PII: S0005-2736(20)30182-6

DOI: <https://doi.org/10.1016/j.bbamem.2020.183342>

Reference: BBAMEM 183342

To appear in: *BBA - Biomembranes*

Received date: 5 February 2020

Revised date: 2 May 2020

Accepted date: 4 May 2020

Please cite this article as: S. Devarajan, M. Meurer, C.W.T. van Roermund, et al., Proteasome-dependent protein quality control of the peroxisomal membrane protein Pxa1p, *BBA - Biomembranes* (2020), <https://doi.org/10.1016/j.bbamem.2020.183342>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# Proteasome-dependent protein quality control of the peroxisomal membrane protein Pxa1p

S. Devarajan<sup>1</sup>, M. Meurer<sup>2</sup>, C.W.T. van Roermund<sup>3</sup>, X. Chen<sup>1</sup>, E. H. Hettema<sup>4</sup>, S. Kemp<sup>3</sup>, M. Knop<sup>2,5</sup> and C. Williams<sup>1\*</sup>

<sup>1</sup>Department of Cell Biochemistry, University of Groningen, the Netherlands

<sup>2</sup>Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), DKFZ-ZMBH Alliance, Heidelberg, Germany

<sup>3</sup>Laboratory Genetic Metabolic Diseases, Amsterdam University Medical Centres, the Netherlands

<sup>4</sup>Department of Molecular Biology, University of Sheffield, Sheffield, United Kingdom

<sup>5</sup>Cell Morphogenesis and Signal Transduction, German Cancer Research Centre (DKFZ), Heidelberg, Germany

\*Corresponding author (c.p.williams@rug.nl)

## Abstract

Peroxisomes are eukaryotic organelles that function in numerous metabolic pathways and defects in peroxisome function can cause serious developmental brain disorders such as adrenoleukodystrophy (ALD). Peroxisomal membrane proteins (PMPs) play a crucial role in regulating peroxisome function. Therefore, PMP homeostasis is vital for peroxisome function. Recently, we established that certain PMPs are degraded by the Ubiquitin Proteasome System yet little is known about how faulty/non-functional PMPs undergo quality control. Here we have investigated the degradation of Pxa1p, a fatty acid transporter in the yeast *Saccharomyces cerevisiae*. Pxa1p is a homologue of the human protein ALDP and mutations in ALDP result in the severe disorder ALD. By introducing two corresponding ALDP mutations into Pxa1p (Pxa1<sup>MUT</sup>), fused to mGFP, we show that Pxa1<sup>MUT</sup>-mGFP is rapidly degraded from peroxisomes in a proteasome-dependent manner, while wild type Pxa1-mGFP remains relatively stable. Furthermore, we identify a role for the ubiquitin ligase Ufd4p in Pxa1<sup>MUT</sup>-mGFP degradation. Finally, we establish that inhibiting Pxa1<sup>MUT</sup>-mGFP degradation results in a partial rescue of Pxa1p activity in cells. Together, our data demonstrate that faulty PMPs can undergo proteasome-dependent quality control. Furthermore, our observations may provide new insights into the role of ALDP degradation in ALD.

**Keywords:** protein degradation, proteasome, ALD, peroxisome, ufd4

## Introduction

Peroxisomes are eukaryotic organelles that encompass a protein-rich matrix bound by a single membrane. Their morphology, abundance and function depends on species and developmental stage [1]. Some well-known peroxisomal functions include fatty acid oxidation and hydrogen peroxide detoxification, but many more exist [2]. Their importance in human health is underlined by the severe diseases such as adrenoleukodystrophy (ALD) caused by defects in peroxisome function [3].

Peroxisome function is largely determined by peroxisomal protein content. Most peroxisomal membrane proteins (PMPs) are synthesized in the cytosol and targeted directly to peroxisomes [4] although a subset of PMPs may be delivered to peroxisomes via the endoplasmic reticulum [5]. PMPs regulate many aspects of peroxisome biology, including peroxisomal protein import [6], peroxisome numbers [7] and small molecule transport into peroxisomes [8]. For peroxisome function, PMP homeostasis is vital; this includes the regulation of targeting but also protein quality control processes and protein degradation. Recently, we demonstrated that the PMPs Pex3p and Pex13p in the yeast *Hansenula polymorpha* are actively down-regulated [9, 10]. Pex3p degradation initiates selective autophagy of peroxisomes while Pex13p degradation is linked to peroxisomal matrix protein import. Both Pex3p and Pex13p are degraded by the Ubiquitin Proteasome System (UPS) [11]. In this system, ubiquitin (Ub) is activated by a ubiquitin-activating enzyme (E1), then transferred to the active site cysteine of an ubiquitin-conjugating enzyme (E2) and finally, Ub is attached to the substrate with the aid of an ubiquitin ligase (E3) [12-14]. Three classes of E3s exist. HECT E3 ligases accept Ub onto an active site cysteine and then transfer Ub to a substrate [15, 16], whereas RING E3 ligases act as bridge between E2 and substrate, allowing Ub transfer to occur [17, 18]. The third class of E3 ligase, known as RING-in-between-RING (RBR) E3s, contain a RING domain, followed by an RBR domain and finally a RING-like domain [19]. These RBR E3s, like HECT E3s, accept Ub from an E2 onto a cysteine in the RING-like domain before transferring it to the substrate [20].

The examples of Pex3p and Pex13p demonstrate that targeted down-regulation of PMPs does occur. However, because peroxisomes are involved in various oxidative metabolic reactions, they can generate large amounts of reactive oxygen species (ROS) such as hydrogen peroxide [21]. Because ROS are toxic compounds which cause damage to biomolecules [22], it is highly likely that PMPs residing in the ROS rich environment of the peroxisome undergo oxidative damage. Therefore, PMP quality control is likely to play a vital role in peroxisome biology yet to date little is known on how misfolded, non-functional or faulty PMPs are targeted for degradation via quality control. Here we have investigated PMP quality control in the yeast *Saccharomyces cerevisiae* using Pxa1p as substrate. Pxa1p is a half-ABC transporter, containing six transmembrane helices and a nucleotide-binding domain (NBD). The heterodimerization of Pxa1p with Pxa2p, another half-ABC transporter, is required for transporting acyl-CoA such as Oleoyl-CoA into peroxisomes [23, 24]. Pxa1p is the homologue of human adrenoleukodystrophy protein (ALDP) [25]. Mutations in ALDP cause ALD [26] and many ALDP mutants are rapidly degraded, likely by the proteasome [27]. This has led to the suggestion that blocking ALDP degradation might constitute a feasible therapeutic approach to treat ALD [27, 28]. However, to date little is known about the mechanisms underlying ALDP instability or degradation.

Using a mutant form of Pxa1p (Pxa1<sup>MUT</sup>) that mimics ALD-causing ALDP mutations, fused to mGFP, we show that Pxa1<sup>MUT</sup>-mGFP is rapidly degraded from peroxisomes. Furthermore, we show that

Pxa1<sup>MUT</sup>-mGFP degradation is dependent on the proteasome while our data also demonstrate a role for the E3 ligase Ufd4p in Pxa1<sup>MUT</sup>-mGFP degradation. Finally, we show that inhibiting Pxa1<sup>MUT</sup>-GFP degradation partially restores Pxa1p function *in vivo*. Taken together, our study demonstrates that faulty PMPs can undergo proteasome-mediated degradation. Furthermore, our observations on Pxa1<sup>MUT</sup>-mGFP degradation may provide new insights into the role of ALDP stability in ALD.

## Results

### *Pxa1<sup>MUT</sup>-mGFP undergoes proteasome-mediated degradation from peroxisomes*

Unlike wild-type (WT) ALDP, many mutant versions of ALDP are unstable and are rapidly degraded [29, 30], suggesting that quality control of faulty peroxisomal fatty acid transporters occurs. To investigate this in *S. cerevisiae*, we chose to study the degradation of the yeast ALDP homologue Pxa1p. For this, we selected two ALD causing mutations in ALDP, a commonly occurring glycine to serine substitution at position 512 (p.Gly512Ser) together with a lysine to arginine substitution at position 513 (p.Lys513Arg), both present in the walker A motif of the NBD ([www.adrenoleukodystrophy.info](http://www.adrenoleukodystrophy.info)). The p.Gly512Ser mutation causes reduced protein stability *in vivo* [31] although importantly, it does not abolish ATP-hydrolysis activity *in vitro* [32]. The p.Lys513Arg mutation also causes protein instability *in vivo* ([www.adrenoleukodystrophy.info](http://www.adrenoleukodystrophy.info)). The corresponding ALDP mutations (p.Gly650Ser and p.Lys651Arg) were both introduced into yeast *PXA1*. We chose to introduce two mutations to maximize the destabilizing effect to Pxa1p. The Gly650Ser/Lys651Arg mutant form of Pxa1p is referred to as Pxa1<sup>MUT</sup>. We chose to fuse Pxa1<sup>MUT</sup> to mGFP (Pxa1<sup>MUT</sup>-mGFP), which allowed us to follow Pxa1<sup>MUT</sup> using both biochemical and microscopy based techniques. Furthermore, the DNA encoding for Pxa1<sup>MUT</sup>-mGFP was integrated into the genome of the *S. cerevisiae* strains used and therefore represents the only copy of *PXA1* in the cells.

Since Pxa1p functions in transporting fatty acyl-CoA, such as Oleoyl-CoA, into peroxisomes for  $\beta$ -oxidation [23, 24], we performed all our experiments using cells grown on oleate containing media, to better understand the turnover of Pxa1<sup>MUT</sup>-mGFP under conditions when the protein is required. For this purpose, *S. cerevisiae* cells were pre-cultivated on glucose medium and shifted to oleate medium, to induce the expression of the proteins required for peroxisomal  $\beta$ -oxidation [33-35]. However, because we performed experiments using deletion mutants that are unable to utilize oleate as carbon source (see below), we used oleate medium containing 0.1% glucose throughout the study, to allow results to be comparable. Therefore unless otherwise stated, oleate medium always contained 0.1% glucose.

First, we investigated whether Pxa1<sup>MUT</sup>-mGFP is properly targeted to peroxisomes. For this, we used fluorescence microscopy to examine the localization of Pxa1<sup>MUT</sup>-mGFP in cells grown on oleate. Pex3-mKate2 (Figure 1A) or DsRed-SKL (Figure S1A) was used as a marker for peroxisomes. As control, we used cells producing an mGFP-tagged version of WT Pxa1p (Pxa1-mGFP). We observed that mGFP spots co-localized with mKate2 spots in strains expressing Pxa1-mGFP (Figure 1A, row 4) or Pxa1<sup>MUT</sup>-mGFP (Figure 1A, row 6) while line profile data indicate a strong correlation between the normalized fluorescent intensity of mGFP and mKate2 (Figure 1A, row 4 and row 6, right), indicating that both Pxa1-fusions correctly target to peroxisomes. Likewise, mGFP spots co-localized with DsRed spots in cells expressing Pxa1<sup>MUT</sup>-mGFP and DsRed-SKL (Figure S1A), confirming that Pxa1<sup>MUT</sup>-mGFP correctly targets to peroxisomes. We also observed larger, more diffuse spots in both mGFP and mKate2 channels

(Figure 1A, red arrows). However, these were also seen in WT cells lacking fluorescent markers (Figure 1A, row 1) and likely represent auto-fluorescence.

The mGFP signal in cells expressing Pxa1<sup>MUT</sup>-mGFP was lower and fewer GFP spots were visible compared to those expressing Pxa1-mGFP (Figure 1A, row 6), which is consistent with the reduced protein levels of Pxa1<sup>MUT</sup>-mGFP compared to those of Pxa1-mGFP (Figure 1B, 1C and S1C). Lower protein levels could suggest either reduction in protein production or reduced protein stability. To examine the stability of Pxa1<sup>MUT</sup>-mGFP we performed chase analysis using the protein synthesis inhibitor cycloheximide (CHX). For this purpose, cells were pre-cultivated on glucose, transferred to oleate containing media (peroxisome inducing conditions) and grown for 11 hrs until an OD<sub>600</sub> of ~1.5. After 11 hrs of growth in oleate containing media, cells were treated with either CHX or DMSO (control), cells were grown further for 6 hrs (Pxa1-mGFP) or 2hrs (Pxa1<sup>MUT</sup>-mGFP) on inducing medium and samples were collected for western blotting.

We observed an increase in Pxa1-mGFP and Pxa1<sup>MUT</sup>-mGFP levels in DMSO-treated cells over time (Figure 2A, DMSO), consistent with the observation that Pxa1-mGFP levels continue to increase until ~36 hrs after transfer of cells to induction medium (Figure S1D). Significantly, Pxa1<sup>MUT</sup>-mGFP was rapidly degraded and displayed a significantly shorter half-life (~15 mins) compared to Pxa1-mGFP (~360 mins or 6 hrs) (Figure 2A, CHX and S1E) in cells treated with CHX, indicating that the mutations introduced into Pxa1p result in protein instability.

Next, we sought to determine whether Pxa1<sup>MUT</sup>-mGFP degradation occurs after targeting to peroxisomes. For this, we imaged CHX treated WT cells co-expressing Pex3-mKate2 and Pxa1-mGFP or Pxa1<sup>MUT</sup>-mGFP. We observed that the number of mGFP positive spots reduced over time in cells expressing Pxa1<sup>MUT</sup>-mGFP (Figure 2B, right panel) while cells expressing Pxa1-mGFP displayed many more mGFP positive spots after 120 mins of CHX treatment (Figure 2B, left panel). The number of mKate2 spots remained stable after CHX treatment in both strains (Figure 2B). These observations suggest that Pxa1<sup>MUT</sup>-mGFP is degraded from peroxisomes. To validate this further, we quantified mGFP and mKate2 fluorescence intensities on peroxisomes in our fluorescent images. We observed that, as expected, the mKate2 intensity remained stable over time in the two strains (Figure 2C). Likewise, the mGFP intensity on peroxisomes in CHX-treated Pxa1-mGFP cells remained stable (Figure 2C, left panel) but decreased rapidly in Pxa1<sup>MUT</sup>-mGFP cells treated with CHX (Figure 2C, right panel). In addition, the mGFP/mKate2 ratio in CHX treated Pxa1<sup>MUT</sup>-mGFP cells decreased rapidly over time but remained stable in Pxa1-mGFP cells after CHX addition (Figure 2D). The rate of the decrease in mGFP intensity in Pxa1<sup>MUT</sup>-mGFP cells treated with CHX appears different from that obtained using western blotting (Figure 2A), likely due to the high background observed in the mGFP channel (Figure 1A, row 1 and 2). Together, these data strongly suggest that Pxa1<sup>MUT</sup>-mGFP is rapidly degraded from peroxisomes.

Since ALDP mutants are thought to be degraded via the proteasome [30], we first examined whether the proteasome has a role in Pxa1<sup>MUT</sup>-mGFP degradation, through the use of a mixture of the proteasome inhibitors MG132 and Bortezomib (Figure 3A and S1F). We assessed Pxa1<sup>MUT</sup>-mGFP turnover in cells lacking Pdr5p (the major drug efflux transporter [36]), to enhance the uptake of inhibitors [37, 38]. In addition, we examined Pxa1<sup>MUT</sup>-mGFP degradation in cells lacking Atg12p (Figure 3B and S1G), which is involved in autophagy [39]. From our CHX chase analysis, we observed that Pxa1<sup>MUT</sup>-mGFP

degradation is inhibited in *pdr5* cells after the addition of proteasome inhibitors (Figure 3A, CHX+MG132+Bortezomib) compared to non-treated cells (Figure 3A, CHX). These data, together with the observation that the deletion of *ATG12* had no effect on Pxa1<sup>MUT</sup>-mGFP turnover (Figure 3B and S1G) demonstrates that the proteasome is involved in Pxa1<sup>MUT</sup>-mGFP degradation. Next, we checked whether ubiquitination has a role in Pxa1<sup>MUT</sup>-mGFP degradation by expressing a mutant form of ubiquitin (Ub<sup>K48R</sup>) in Pxa1<sup>MUT</sup>-mGFP cells, to inhibit poly-ubiquitin chain formation on the substrate and subsequent degradation by the proteasome [40]. We observed that Pxa1<sup>MUT</sup>-mGFP turnover is reduced in cells expressing Ub<sup>K48R</sup>, compared to Ub expressing cells (Figure 3C and S1G). However, we were unable to detect ubiquitinated Pxa1<sup>MUT</sup>-mGFP (Figure 3D). Possibly ubiquitinated Pxa1<sup>MUT</sup>-mGFP is below the level of detection because of the high speed by which Pxa1<sup>MUT</sup>-mGFP is degraded. In summary, these data demonstrate that Pxa1<sup>MUT</sup>-mGFP undergoes rapid, proteasome-mediated degradation from peroxisomes.

#### *Identifying components required for Pxa1-tFT degradation*

To gain the first insights into mechanisms of Pxa1<sup>MUT</sup>-mGFP quality control, we set out to identify components required for Pxa1<sup>MUT</sup>-mGFP degradation using a tandem fluorescent protein timer (tFT). A tFT is a fusion of two fluorescent proteins; the slow maturing mCherry and the rapid maturing sfGFP (Figure 4A). When tagged to a protein of interest, the mCherry/sfGFP ratio provides information on protein stability. tFT fusions undergoing fast turnover are degraded prior to mCherry maturation, resulting in a low mCherry/sfGFP ratio, whereas the mCherry/sfGFP ratio increases for proteins with slower turnover [41]. Similar to Pxa1<sup>MUT</sup>-mGFP, Pxa1-tFT levels in cells were much lower compared to Pxa1-mGFP levels (Figure 4B) while Pxa1-tFT was rapidly degraded in cells treated with CHX (Figure 4C and S1H). The turnover of tFT-tagged Pex11p, a stable PMP [9], was slower in comparison (Figure 4C and S1H). Furthermore, the GFP immunoreactive band at around 33kDa observed with samples containing Pxa1-tFT (Figure 4B and S1H, marked \*\*) is derived from incomplete tFT processing by the proteasome [42], suggesting a role for the proteasome in Pxa1-tFT turnover. From these data, we conclude that, similar to Pxa1<sup>MUT</sup>-mGFP, Pxa1-tFT undergoes proteasome-mediated degradation and for this reason, we did not create a Pxa1-tFT fusion containing the Gly650Ser/Lys651Arg mutations.

Next, we investigated the stability of Pxa1-tFT in a library of 132 strains that lack a protein involved in protein degradation or which contained a mutant version of a protein involved in protein degradation (in case the deletion was lethal) using a synthetic genetic array [43, 44]. This library represents a large fraction of the factors known to have a role in the degradation of proteins in yeast (see Table S2 for details on which strains were included in the library). The effect of the mutations on the stability of Pxa1-tFT was examined using mCherry/sfGFP intensity ratios obtained from whole colonies after one, two and three days of growth on oleate/glucose plates. These mCherry/sfGFP ratios were used to calculate a heat map of Z-scores (Figure 4D), which depicts the stability of Pxa1-tFT in each strain. A strain displaying similar Pxa1-tFT stability as in WT cells would have a Z-score of 0 while strains with enhanced stability would exhibit a Z-score >0 (see materials and methods). Mutant strains that displayed an increase in Z-score >1.0 on two of the three days tested were considered as potential candidates that increased Pxa1-tFT stability. Pxa1-tFT stability was increased in cells lacking functional proteasomes (*pre2*, *pre6*, *rpn10*, *rpt6-25* and *ubp6* cells) but not in cells lacking Atg12p (Figure 4D), confirming a role for the proteasome in

Pxa1-tFT stability. These results demonstrate that our tFT analysis is a valid way to identify factors potentially involved in Pxa1<sup>MUT</sup>-mGFP degradation.

Pxa1-tFT stability was increased in strains deleted for genes coding for the peroxisomal E2 Pex4p or one of the three peroxisomal E3 ligases Pex2p, Pex10p and Pex12p [45] (Figure 4D). Consistent with this, Pxa1-tFT protein levels were enhanced in *pex2* and *pex4* cells (Figure 4E), thereby confirming our tFT data. Roles for these proteins in PMP ubiquitination/degradation have already been reported [9, 10, 46], suggesting that common mechanisms may govern PMP ubiquitination and degradation. However, Pxa1-tFT stability was also enhanced in cells lacking a number of de-ubiquitinating enzymes (DUBs), which could suggest a role for these DUBs in the deubiquitination of Pxa1<sup>MUT</sup>-mGFP prior to proteasomal degradation. In addition, cells lacking the E3s Nam7p, Dma2p, Tul1p and Ufd4p, the E3 co-factor proteins Ela1p and Skp2p and the ubiquitin-binding protein Dsk2p (Supplementary Table S2), factors not previously associated with peroxisomes, also displayed enhanced Pxa1-tFT stability. Overall, our tFT analysis identified factors potentially involved in the degradation of faulty Pxa1p.

#### *Components involved in Pxa1-tFT stability play a role in Pxa1<sup>MUT</sup>-mGFP degradation*

Previously we demonstrated that the peroxisomal ubiquitination machinery is required for the degradation of the PMPs Pex3p and Pex13p [9, 10]. Because deletion of *PEX4*, *PEX2*, *PEX10* or *PEX12* results in Pxa1-tFT stabilization (Figure 4D and 4E), we were interested to investigate whether they also had a role in Pxa1<sup>MUT</sup>-mGFP degradation. Indeed, Pxa1<sup>MUT</sup>-mGFP levels were enhanced in cells deleted for *PEX2* or *PEX4* (Figure 5A and S2A) while Pxa1<sup>MUT</sup>-mGFP turnover was also inhibited in these cells (Figure 5B and S2B), validating our tFT data as well as indicating a role for these peroxisomal proteins in Pxa1<sup>MUT</sup>-mGFP degradation. Furthermore, Pxa1<sup>MUT</sup>-mGFP localised to peroxisomes in these strains (Figure 5C), indicating that stabilisation did not arise from mistargeting to other cell compartments. However, because cells deleted for *PEX2* or *PEX4* also lack functional peroxisomes [47], we investigated the impact of peroxisome function alone on Pxa1<sup>MUT</sup>-mGFP turnover by assessing the stability and turnover of Pxa1<sup>MUT</sup>-mGFP in *pex5* cells, which also lack functional peroxisomes [48]. Our data demonstrate that Pxa1<sup>MUT</sup>-mGFP degradation was inhibited in *pex5* cells (Figure 5A, B and S2B), suggesting that Pxa1<sup>MUT</sup>-mGFP degradation may be linked to peroxisome function. Again, Pxa1<sup>MUT</sup>-mGFP targeting was not impaired in *pex5* cells (Figure 5C). We observed that Pex3-mKate2 levels are comparable in WT, *pex2*, *pex4* and *pex5* cells (Figure S2C), suggesting that the effect of these deletion strains is not general for all PMPs. Nevertheless, these data indicate that studying Pxa1<sup>MUT</sup>-mGFP turnover in strains deficient in peroxisome function could be challenging because any effects may potentially be indirect.

Therefore, we turned to investigate the role of candidates identified in our tFT analysis not previously associated with peroxisome function, including Ufd4p, Nam7p, Ela1p, Dsk2p, Skp2p, Tul1p and Dma2p. Interestingly, we observed that Pxa1<sup>MUT</sup>-mGFP levels were significantly higher in cells lacking Ufd4p (Figure 6A and S2A). Deletion of *ELA1*, *DSK2*, *SKP2*, *TUL1* or *DMA2* did not impact significantly on Pxa1<sup>MUT</sup>-mGFP levels (Figure 6A and S2A) and were not investigated further. Furthermore, Pxa1<sup>MUT</sup>-mGFP levels were significantly lower in the *NAM7* deletion strain compared to the WT (Figure 6A and S2A). However, because we were specifically interested in UPS mutants that

increased the stability of Pxa1<sup>MUT</sup>-mGFP, the role of *NAM7* in Pxa1<sup>MUT</sup>-mGFP stability was not investigated further.

Significantly, we observed that *ufd4* cells retain the ability to grow on media containing oleate as sole carbon source (Figure 6B), indicating that they contain functional peroxisomes and hence that Pxa1<sup>MUT</sup>-mGFP stabilization in this strain does not stem from a deficiency in peroxisome function. Since Ufd4p is a cytosolic E3 ligase that regulates the degradation of faulty proteins [49], but it has not been linked to peroxisome function, we chose to investigate the role of Ufd4p in Pxa1<sup>MUT</sup>-mGFP degradation further. We performed CHX chase analysis and observed that Pxa1<sup>MUT</sup>-mGFP degradation is inhibited in *ufd4* cells compared to WT cells (Figure 6C and S2B). Furthermore, using fluorescence microscopy in combination with CHX chase assays, we investigated the localization and turnover of Pxa1<sup>MUT</sup>-mGFP in *ufd4* cells. As can be seen in Figure 6D (t=0, left panel), mGFP spots co-localize with mKate2 spots in *ufd4* cells. In addition, line profile data indicate strong correlation between the normalized fluorescent intensity of mGFP and mKate2, demonstrating that Pxa1<sup>MUT</sup>-mGFP is indeed localised to peroxisomes in *ufd4* cells (Figure 6D). The peroxisomal localisation of Pxa1<sup>MUT</sup>-mGFP in *ufd4* cells was confirmed using DsRed-SKL as a peroxisomal marker (Figure S1A). Significantly, cells deleted for *UFD4* display increased numbers of mGFP spots after 120 mins of CHX treatment, compared to the WT strain (Figure 6D, right panel; t=120 mins). Furthermore, mGFP spots in *ufd4* cells co-localize with mKate2 spots after 120 mins of CHX treatment (Figure 6D, left panel), demonstrating that Pxa1<sup>MUT</sup>-mGFP accumulates on peroxisomes in these cells. Together, these data establish that the E3 ligase Ufd4p is involved in the proteasome-dependent degradation of Pxa1<sup>MUT</sup>-mGFP.

#### *Inhibiting Pxa1<sup>MUT</sup>-mGFP degradation enhances peroxisomal $\beta$ -oxidation*

Around 70% of the mutant forms of ALDP are unstable and are degraded [30, 50]. However, many of these mutants retain a certain level of functionality [32]. This has led to the hypothesis that blocking ALDP degradation could enhance ALDP activity in cells and be beneficial for ALD patients [27-29]. Our data clearly indicate that Pxa1<sup>MUT</sup>-mGFP builds up at peroxisomes when its degradation is inhibited in *ufd4* cells. Hence, we reasoned that we could use our experimental setup as proof of principle and measured the capacity of WT and *ufd4* cells expressing Pxa1-mGFP or Pxa1<sup>MUT</sup>-mGFP to perform  $\beta$ -oxidation (Figure 7A). Pxa1<sup>MUT</sup>-mGFP in WT cells displayed reduced activity in comparison to Pxa1-mGFP (Figure 7A) although higher than *pxa1* cells, indicating that importantly, Pxa1<sup>MUT</sup>-mGFP retains a degree of functionality. Significantly, *ufd4* cells expressing Pxa1<sup>MUT</sup>-mGFP exhibited an increase in  $\beta$ -oxidation activity of around 15% compared to the activity of WT.Pxa1<sup>MUT</sup>-mGFP cells (Figure 7A). We also observed that  $\beta$ -oxidation appeared enhanced in *ufd4* cells expressing Pxa1-mGFP compared to WT cells, although statistical analysis suggested that this increase was not significant (Figure 7A). To investigate further, we determined the levels of Pxa1-mGFP in WT and *ufd4* cells expressing Pxa1-mGFP (Figure 7B), observing that these levels were indeed increased in *ufd4* cells. Significantly, Pex14p levels were not affected by *ufd4* deletion (Figure 7B), indicating that the effect is likely to be specific for Pxa1-mGFP.

Overall, our results provide proof of principle that blocking Pxa1<sup>MUT</sup>-mGFP degradation can partially restore Pxa1<sup>MUT</sup>-mGFP function in cells, supporting the view that inhibiting ALDP degradation may be a promising therapeutic avenue to explore to target ALD.

## Discussion

Here we have demonstrated that a faulty version of the peroxisomal fatty acid transporter Pxa1p is targeted for proteasome-dependent degradation. Pxa1<sup>MUT</sup>-mGFP, our chosen substrate, is rapidly degraded from peroxisomes. An important question remains how Pxa1<sup>MUT</sup>-mGFP is recognized for degradation? The mutations introduced into Pxa1p (Gly650Ser/Lys651Arg) are present in the conserved walker A motif of the NBD [51]. Mutation of either these conserved lysine or glycine residues compromises both the ATP hydrolysis and substrate translocation activity of ABC transporters [52-54], including ALDP [32]. Hence, the substitutions we introduced into Pxa1<sup>MUT</sup>-mGFP likely reduce ATP hydrolysis and hence transport activity, which in turn could allow Pxa1<sup>MUT</sup>-mGFP to be recognized for degradation. However, Pxa1p forms a heterodimer with Pxa2p and deletion of *PXA2* decreases the stability of Pxa1p [55], indicating that Pxa2p binding is required for Pxa1p stability. Therefore, it is equally possible that the substitutions in Pxa1<sup>MUT</sup>-mGFP inhibit binding to Pxa2p, which in turn allows Pxa1<sup>MUT</sup>-mGFP to be recognized for degradation. Interestingly, Byeon et al. reported that mutating the walker A lysine in muscle adenylate kinase results in a conformational change in the NBD [52] while recent work on the bacterial transporter MJ0796 demonstrated that walker A lysine mutations impact on both ATP hydrolysis and homo-dimerization [54]. Hence, we speculate that the introduced mutations in Pxa1<sup>MUT</sup>-mGFP result in a conformational change in Pxa1p, which could allow the protein to be recognized for degradation. Identifying which factors are involved in the recognition of faulty peroxisomal fatty acid transporters will provide valuable insights into the mechanisms underlying their degradation.

Our data show that the addition of proteasome inhibitors significantly reduce Pxa1<sup>MUT</sup>-mGFP turnover, demonstrating a role for the proteasome in Pxa1<sup>MUT</sup>-mGFP degradation (Figure 3A). While the data on the ubiquitin mutant (Ub<sup>K48</sup>) suggests that ubiquitination is involved in Pxa1<sup>MUT</sup>-mGFP degradation (Figure 3C), our attempts to detect ubiquitinated forms of Pxa1<sup>MUT</sup>-mGFP proved unsuccessful (Figure 3D). Notably, ubiquitinated forms of ALDP carrying the R617H or H667D mutations could also not be detected [30], even though these mutants were likely degraded by the proteasome. There could be two possible explanations for this: Pxa1<sup>MUT</sup>-mGFP is ubiquitinated but that the ubiquitinated form of Pxa1<sup>MUT</sup>-mGFP is below the limit of detection, or that the ubiquitination of another protein could facilitate the degradation of Pxa1<sup>MUT</sup>-mGFP. The latter mode of degradation has been proposed for several substrates of the proteasome. Dang et al., reported that instead of A3G, its binding partner viral infectivity factor (Vif) undergoes poly-ubiquitination and this could be critical for A3G proteasomal degradation [56], proposing that poly-ubiquitinated Vif might act as an adaptor protein to bring A3G to the proteasome for degradation [57]. Another protein that may be degraded via a similar mechanism is the retinoblastoma tumour suppressor protein (Rb) [58]. Rb is thought to be targeted for proteasomal degradation by the ubiquitination of its binding partner, human papillomavirus protein E7 [58, 59]. Pxa2p forms a heterodimer with Pxa1p [23, 24], but we do not suspect that Pxa2p ubiquitination is required for Pxa1<sup>MUT</sup>-mGFP degradation because loss of Pxa2p does not inhibit Pxa1p degradation but instead decreases the stability of Pxa1p [55]. Clearly further work is required to investigate how ubiquitin contributes to the proteasome-mediated degradation of Pxa1<sup>MUT</sup>-mGFP.

Based on the results of our tFT screening, several proteins not previously associated with peroxisomal function were identified that could play a role in Pxa1-tFT stability (Figure 4C). Of these, only loss of Ufd4p, a cytosolic E3 ligase involved in the degradation of faulty proteins [49], significantly increased the stability of Pxa1<sup>MUT</sup>-mGFP (Figure 6A), indicating that Ufd4p is involved in Pxa1<sup>MUT</sup>-mGFP degradation. Although future work needs to investigate the mechanisms by which Ufd4p controls Pxa1<sup>MUT</sup>-mGFP degradation, we consider it significant that a cytosolic E3 ligase could regulate the turnover of a faulty PMP because this indicates that general cellular quality control pathways can facilitate the degradation of faulty PMPs. While the data we present here concern the degradation of a mutant form of Pxa1p, we consider it unlikely that the sole purpose of PMP quality control is the degradation of mutant PMPs; we consider it more likely that damaged PMPs undergo quality control. As previously mentioned, the ROS rich environment of the peroxisome could result in the oxidative damage of proteins, which could suggest that damaged Pxa1p undergoes PMP quality control. In line with this, although Pxa1-mGFP is much more stable than Pxa1<sup>MUT</sup>-mGFP in our CHX experiments, degradation of Pxa1-mGFP does occur (Figure 2A) while Pxa1-mGFP levels are higher in *ufd4* cells compared to WT cells (Figure 7B). Therefore, it is plausible that Pxa1<sup>MUT</sup>-mGFP is targeted for degradation via quality control mechanisms that usually acts upon damaged Pxa1p because Pxa1<sup>MUT</sup>-mGFP is impaired in function.

Deletion of *UFD4* does not fully inhibit the degradation of Pxa1<sup>MUT</sup>-mGFP. Similarly, Pxa1<sup>MUT</sup>-mGFP degradation appears only partly reduced in cells lacking the peroxisomal E3 ligase Pex2p. This could suggest that two pathways target Pxa1<sup>MUT</sup>-mGFP for degradation, one requiring Ufd4p and the other involving Pex2p or perhaps that Pex2p and Ufd4p collaborate to facilitate Pxa1<sup>MUT</sup>-mGFP degradation. Ufd4p can team up with Ubr1p, a RING E3, to facilitate the degradation of Mgt1p, a DNA repair demethylase [60]. However, the impact of peroxisome function on Pxa1<sup>MUT</sup>-mGFP degradation remains to be determined, meaning that further data on the role of Pex2p (and other members of the peroxisomal ubiquitination machinery) are required to validate this hypothesis. Nevertheless, a model that depicts Pex2p and Ufd4p teaming up to degrade faulty PMPs remains an attractive one.

Mutations in gene sequences can result in formation of faulty proteins, which could pose serious threats to the cell, for two reasons. One reason is the loss of protein activity. However, there is also gain-of-toxic function that is unrelated to the protein's function and which has become increasingly relevant to human disease [61]. Faulty proteins often expose hydrophobic regions normally buried within the core [62] that may take part in unwanted protein-protein interactions, resulting in protein aggregation [63]. To minimize such harmful effects, cell employs protein quality control systems to remove faulty proteins [64]. For instance, mutations at position F508 in Cystic fibrosis transmembrane conductance regulator (CFTR), which increase the tendency of CFTR to aggregate but do not inhibit activity completely [65, 66], result in rapid protein degraded [67]. However, the rapid degradation of mutant CFTR leaves cells devoid of CFTR molecules, eventually resulting in the severe condition cystic fibrosis [68] and several lines of research have focused on blocking CFTR degradation as potential treatment for cystic fibrosis [69]. Similarly, many ALDP mutant proteins that cause ALD are unstable, leading to the suggestion that blocking ALDP degradation could represent a novel treatment for ALD [27]. Indeed, a subset of ALDP mutant proteins in patient cells become stable under low-temperature culture conditions and exhibit proper peroxisomal localization [27] while they also display increased residual  $\beta$ -oxidation activity [28]. Though unstable, a

significant proportion of ALDP mutants retain a certain degree of function [27, 32]. In line with this, our data demonstrate that Pxa1<sup>MUT</sup>-mGFP cells display increased  $\beta$ -oxidation compared to *pxa1* cells (Figure 7A), indicating that Pxa1<sup>MUT</sup>-mGFP is partly functional. Furthermore, stabilizing Pxa1<sup>MUT</sup>-mGFP, through the deletion of *UFD4*, enhances peroxisomal  $\beta$ -oxidation in cells, which would indeed support the notion that blocking ALDP mutant degradation might constitute a feasible therapeutic approach to treat ALD. However, Yamada et al. indicated that proteasome inhibitors enhance the stability of certain ALDP mutants but did not increase peroxisomal  $\beta$ -oxidation in the corresponding cells [29]. While these results may seem contradictory to those reported here, it is important to note that the location where the mutants build up upon stabilization is critical in determining whether stabilization will result in enhanced activity. Yamada and co-workers did not address this in their study [29] and it is possible that these ALDP mutants are stabilized elsewhere in the cell. Hence, further work on the mechanism of ALDP degradation is therefore needed to understand at which point blocking ALDP mutant degradation could positively affect ALDP activity. Nevertheless, our data demonstrate that *UFD4* deletion results in a build-up of Pxa1<sup>MUT</sup>-mGFP at the peroxisomal membrane and significantly, a human homolog of Ufd4p, known as TRIP12 [70], is involved in the degradation of a range of different proteins [71-73]. It would therefore be interesting to investigate whether TRIP12 has a role in ALDP degradation and if so, whether blocking TRIP12 dependent ALDP mutant degradation improves  $\beta$ -oxidation in ALD patients.

In summary, we have demonstrated that a faulty peroxisomal fatty acid transporter undergoes proteasome-mediated degradation and identify Ufd4p as playing an important role in facilitating this degradation. In addition, these results may help to shed new light on the role of ALDP degradation in ALD.

## Materials and Methods

### *Construction of plasmids and S. cerevisiae strains*

*S. cerevisiae* transformations were performed with the Lithium acetate method, as described previously [74]. *S. cerevisiae* strains and plasmids used in this study are listed in Table 1 and 2 respectively. The primers used in the study are listed in Table S1. Phusion DNA polymerase (Thermo Scientific) was used for the amplification of gene fragments.

The *S. cerevisiae* WT.Pxa1-mGFP strain was constructed as follows. PCR was performed on pHIPZ-mGFP using the Pxa1-mGFP Fw and Pxa1-mGFP Rev primers to amplify the C-terminal region of *PXA1* together with the Zeocin resistance cassette (*bleMX6*) and the mGFP coding sequences and the obtained PCR fragment was transformed into the yMaM330 strain. The plasmid pGW053 was constructed as follows: the genomic region of the *PXA1* gene was amplified by PCR using Forward primer VIP1080, 485 bp upstream of open reading frame and Reverse primer VIP1081, 192 bp downstream of ORF. This was inserted into Ycplac111 using gap repair between EcoR1 and HindIII sites, resulting in pGW046. This plasmid was used as template for site directed mutagenesis to generate Pxa1 G650S/K651R using VIP672 and VIP673, producing pGW053. For the construction of *S. cerevisiae* WT.Pxa1<sup>MUT</sup>-mGFP, first a recombinant plasmid pHIPZ-Pxa1<sup>MUT</sup>-mGFP was constructed. PCR was performed on pGW053 using Pxa1<sup>MUT</sup> Fw and Pxa1<sup>MUT</sup> Rev primers to amplify the C-terminal region of *PXA1* (carrying the two mutations *G650S/K651R*) and to introduce PciI and BglII sites. The resulting DNA fragment, digested with PciI and BglII, was cloned into PciI/ BglII cut pHIPZ-mGFP to generate pHIPZ-Pxa1<sup>MUT</sup>-mGFP. PCR was

then performed on pHIPZ-Pxa1<sup>MUT</sup>-mGFP using Int\_Pxa1<sup>MUT</sup> Fw and Int\_Pxa1<sup>MUT</sup> Rev to amplify the Pxa1<sup>MUT</sup>-mGFP fragment and the obtained PCR product was then transformed into the yMaM330 strain. The obtained PCR fragment was also transformed into *pdr5*, *atg12* and *ufd4* strains to *pdr5*.Pxa1<sup>MUT</sup>-mGFP, *atg12*.Pxa1<sup>MUT</sup>-mGFP and *ufd4*.Pxa1<sup>MUT</sup>-mGFP respectively. The positive transformants of WT.Pxa1<sup>MUT</sup>-mGFP, *pdr5*.Pxa1<sup>MUT</sup>-mGFP, *atg12*.Pxa1<sup>MUT</sup>-mGFP and *ufd4*.Pxa1<sup>MUT</sup>-mGFP were checked both by colony PCR and sequencing. In addition, PCR fragment was also transformed into *nam7*, *ela1*, *dsk2*, *skp2*, *dma2* and *tull1* cells to generate the mutant strains expressing Pxa1<sup>MUT</sup>-mGFP.

The *S. cerevisiae* Pxa1-tFT strain was generated as follows. PCR was performed on pMaM168 to amplify C-terminal region of *PXA1* and tFT tagging module using primers Pxa1-tFT Fw and Pxa1-tFT Rev. The generated PCR product was then transformed into yMaM330. Strains expressing Pex3-mKate2 were constructed as follows. Pex3-mKate2 cassette consisting of C-terminal region of *PEX3*, hygromycin resistance gene (*hphMX*) and mKate2 coding sequences was amplified from pHIPH-Pex14mKate2 using primers Pex3-mKate Fw and Pex3-mKate Rev. The generated PCR fragment was transformed into WT, WT.Pxa1-mGFP, WT.Pxa1<sup>MUT</sup>-mGFP and *ufd4*.Pxa1<sup>MUT</sup>-mGFP. Furthermore, the PCR fragment was also transformed into *pex2*, Pxa1<sup>MUT</sup>-mGFP, *pex4*, Pxa1<sup>MUT</sup>-mGFP and *pex5*, Pxa1<sup>MUT</sup>-mGFP strains, which were generated as described below

*S. cerevisiae* WT.Pxa1<sup>MUT</sup>-mGFP and *ufd4*.Pxa1<sup>MUT</sup>-mGFP strains expressing DsRed-SKL were constructed as follows. First, the PCR cassette (consisting of *TEF* promoter and DsRed-SKL coding sequences) was digested NotI/SalI and cloned into NotI/SalI cut pHIPX7-DsRed-SKL to create pHIPH7-DsRed-SKL. The PCR cassette containing *TDH3* promoter sequence was amplified from pP<sub>TDH3</sub>-GFP-SKL was digested with NotI/BamHI and cloned into NotI/BamHI cut pHIPH7-DsRed-SKL, to create pHIPH8-DsRed-SKL. The resulting plasmid after linearization with MunI was transformed into WT.Pxa1<sup>MUT</sup>-mGFP and *ufd4*.Pxa1<sup>MUT</sup>-mGFP strains to generate WT.Pxa1<sup>MUT</sup>-mGFP. DsRedSKL and *ufd4*.Pxa1<sup>MUT</sup>-mGFP. DsRed-SKL respectively. In these strains, the expression of DsRed-SKL was under the control of *TDH3* promoter.

*S. cerevisiae* WT.Pxa1<sup>MUT</sup>-mGFP+MycUb and WT.Pxa1<sup>MUT</sup>-mGFP+MycUbK48R strains were constructed as follows. First, the Yeast episomal plasmids (*Y<sub>EP</sub>*) expressing MycUb and MycUbK48R from the *CUP1* promoter were constructed: the *CUP1* promoter coding sequence was amplified from pCGCN-FAA4 using primers CUP1\_Fw and CUP1\_Rev, digested with NotI/BamHI and cloned into NotI/BamHI cut pRDV1 (MycUb) or pRDV2 (MycUbK48R). The resulting vectors were then used to amplify Pcup1-MycUb and Pcup1-MycUbK48R sequences individually using primers CUP1\_Fw and MycUb/UbK48R\_Rev and these PCR fragments were digested with NotI and SacI and cloned into NotI/SacI cut pRG226 (Addgene, 64529). The *Y<sub>EP</sub>*-P<sub>CUP1</sub>-MycUbK48R plasmid was transformed into the WT.Pxa1<sup>MUT</sup>-mGFP strain to generate WT.Pxa1<sup>MUT</sup>-mGFP+MycUbK48R. The *Y<sub>EP</sub>*-P<sub>CUP1</sub>-MycUb plasmid was transformed individually into WT.Pxa1<sup>MUT</sup>-mGFP, *pdr5*.Pxa1<sup>MUT</sup>-mGFP and *pdr5* strains to generate WT.Pxa1<sup>MUT</sup>-mGFP+MycUb, *pdr5*.Pxa1<sup>MUT</sup>-mGFP + MycUb and *pdr5* + MycUb respectively.

#### Construction of *S. cerevisiae* deletion strains

The *pxa1* deletion strain was constructed by replacing the *PXA1* region with the hygromycin resistance gene (*hphMX*). A PCR fragment containing the hygromycin resistance gene and *PXA1* flanking regions

were amplified from pHIPH-Pex14mKate2 using primers DPxa1\_Fw and DPxa1\_Rev. The resulting *PXA1* deletion cassette was transformed into yMaM330. For the construction of *pex5.Pxa1<sup>MUT</sup>-mGFP*, the *PEX5* deletion cassette (geneticin resistance gene and *PEX5* flanking regions) amplified from pFa6AkanMX6 using primers DPex5\_Fw and DPex5\_Rev was transformed in WT.Pxa1<sup>MUT</sup>-mGFP.

*S. cerevisiae pex2* and *pex4* strains expressing Pxa1<sup>MUT</sup>-mGFP or Pxa1-tFT were constructed as follows. The *pex2* and *pex4* deletion cassettes consisting of geneticin resistance cassette (*kanMX*) and *PEX2* or *PEX4* flanking regions were amplified from pFa6AkanMX6 using DPex2\_Fw and DPex2\_Rev (for *PEX2* deletion cassette) and DPex4\_Fw and DPex4\_Rev (for *PEX4* deletion cassette). The obtained deletion cassettes were then transformed individually into WT.Pxa1<sup>MUT</sup>-mGFP and Pxa1-tFT strains to generate *pex2.Pxa1<sup>MUT</sup>-mGFP*, *pex4.Pxa1<sup>MUT</sup>-mGFP*, *pex2.Pxa1-tFT* and *pex4.Pxa1-tFT* strains.

For the construction of *atg12.Pxa1-tFT* strain, deletion cassette consisting of geneticin resistance cassette (*kanMX*) and *ATG12* flanking regions was amplified from pFa6AkanMX6 using primers DAtg12\_Fw and DAtg12\_Rev (for *ATG12* deletion cassette). The obtained deletion cassette was then transformed into Pxa1-tFT to generate *atg12.Pxa1-tFT* strain.

All gene integrations were confirmed by colony PCR using Phire Hot Start II DNA polymerase (Thermo Fisher Scientific) and gene deletions were checked by colony PCR as well as southern blotting analysis of chromosomal DNA, using the ECL Direct Nucleic Acid Labelling and Detection system (Thermo Fisher Scientific), according to the protocol provided by the manufacturer.

#### Growth conditions

The *Escherichia coli* strain DH5 $\alpha$  was used for cloning purposes. *E. coli* cells were grown in LB supplemented with 100  $\mu$ g/ml Ampicillin at 37 °C. Yeast transformants were selected on YPD plates containing 2% agar and 100  $\mu$ g/ml Zeocin (Invitrogen), 150  $\mu$ g/ml Geneticin (Invitrogen) or 300  $\mu$ g/ml Hygromycin (Invitrogen) or on YND plates containing 6.7 g/L yeast nitrogen base without amino acids (YNB, Difco), 5g/L D- glucose monohydrate (Sigma-Aldrich), 2% agar and 30 mg/L Leucine, 20 mg/L Histidine and 20 mg/L Methionine or 30 mg/L Uracil, when required.

For all the experiments, yeast cells were initially cultured at 30°C on YM2 medium (6.7 g/L YNB, 1% casein hydrolysate (Sigma-Aldrich), 60 mg/L uracil, 60 mg/L tryptophan) containing either 2% or 0.3% (w/v) glucose. To induce peroxisome proliferation, cells grown on YM2 medium plus 0.3% glucose were transferred to YNO-glucose medium (6.7 g/L YNB, 1% casein hydrolysate, 60 mg/L uracil, 60 mg/L tryptophan, 0.05% tween, 0.1% oleate and 0.1% glucose). For strains expressing Myc tagged ubiquitin: MycUb and MycUb<sup>K48R</sup> under the control of *CUPI* promoter and uracil coding gene, *URA3* (Table 1), cells were pre-cultured at 30°C on YM2 medium (lacking uracil) plus 0.3% glucose and then grown on YNO-glucose medium (lacking uracil) to an OD<sub>600</sub> of 1.5. To inhibit protein synthesis, cells were treated with cycloheximide (CHX, Sigma-Aldrich) to a final concentration of 6 mg/ml. To inhibit proteasome, cells were treated with 70  $\mu$ M of MG1232 (Sigma-Aldrich) and 70  $\mu$ M of Bortezomib (Selleckchem). Where indicated, an equal amount of DMSO (control for CHX) was added to cells. For spot assays, yeast strains were grown overnight on YM2 medium containing 2% glucose and shifted to YM2 medium plus 0.3% glucose. After 6h of growth in YM2 plus 0.3 glucose, yeast cells were spotted onto oleate plates containing 6.7 g/L YNB, 0.1% yeast extract, 0.1% oleate, 0.05% Tween, 2% agar and when required uracil (30 mg/L),

leucine (60 mg/L), methionine (20 mg/L) and histidine (20 mg/L) was added. Plates were incubated at 30°C for 7 days before imaging.

#### *Preparation of yeast TCA lysates*

Cell extracts of TCA-treated cells were prepared for SDS-PAGE as described previously [75]. SDS-PAGE and western blotting were performed by established methods. Equal volume of samples were loaded per lane and blots were probed with antibodies against mGFP (Santa Cruz Biotech, sc-9996), pyruvate carboxylase 1 (Pyc), Pex14p, rabbit polyclonal antisera raised against the Myc tag (Santa Cruz Biotech, sc-789) or HA tag (Sigma, H6908). Secondary goat anti-rabbit (Thermo Fisher Scientific, 31460) or goat anti-mouse (Thermo Fisher Scientific, 31430) antibodies conjugated to horseradish peroxidase or alkaline phosphatase were used for detection. Pyc was used as a loading control.

#### *Quantification of Western blots*

Western blots were scanned using a densitometer (Bio-Rad, GS-710) and protein levels were quantified using Image J software (<https://imagej.nih.gov/ij/>). The intensity of each band measured was normalized by dividing by the intensity of the corresponding Pyc band (loading control). The normalized Pxa1<sup>MUT</sup>-mGFP values were compared to Pxa1-mGFP values, which was set to 1. The levels of Pxa1<sup>MUT</sup>-mGFP in mutant cells are displayed relative to Pxa1<sup>MUT</sup>-mGFP levels in WT (set to 1). For CHX experiments, the normalized values at time point 0 (T0) was set to 1.0 and values obtained after CHX addition at indicated time points are displayed as a fraction of T0 values. Standard deviations were calculated using Excel. Significance was determined using two tailed student's t-test. \* represents P-values < 0.05, \*\* represents P-values < 0.01, and \*\*\* represents P-values < 0.001. The data presented are derived from three independent experiments.

#### *tFT screening with UPS deletion library*

Tandem fluorescent protein timers (tFT): mCherry and sfGFP were endogenously tagged to Pxa1 as described [76]. By the use of a pinning robot (Singer Instruments), Pxa1-tFT was crossed to UPS deletion library or an array of haploid strains consisting of knockout, temperature sensitive (*ts*) and Decreased Abundance by mRNA perturbation (DAmP) alleles of individual components of the Ubiquitin Proteasome System (UPS) [44, 77, 78]. In addition, Pxa1-tFT was crossed to a control strain expressing *kanMX* selection marker from the *ura3Δ* locus, referred to as wild-type (WT). Screens were performed in 1536 format, with four technical replicates of each cross arranged next to each other. The selection of diploids, sporulation and the selection of haploids carrying Pxa1-tFT and a genetic perturbation, was performed by sequential pinning on appropriate selective media as described [79], followed by seamless marker excision [76]. Using an Infinite M1000 Pro plate reader equipped with automatic plate loading stacker (Tecan) and custom temperature control chamber, mCherry intensity (587/10 nm excitation, 610/10 nm emission) and sfGFP intensity (488/10nm excitation, 510/10 nm emission) was measured from colonies grown on a modified YNO-glucose medium containing (6.7 g/L YNB, 2g/L amino acid dropout mix (-LEU), 0.05% tween, 0.1% oleate, 0.1% glucose and 2% agar). First set of measurements were taken after 24 h of growth and measurements were taken every 24 h until 72 h (3 days).

Whole colony fluorescence intensities (mCherry and sfGFP), obtained from UPS mutant crossed to Pxa1-tFT, were corrected for auto fluorescence by subtracting the measurements of a corresponding mutant crossed to the control strain, yMaM344 (expressing non-fluorescent protein). The median value was calculated out of the four technical replicates. The corrected values of mCherry divided by the sfGFP values yielded a ratio, representing the stability of Pxa1-tFT in the UPS mutants. Similarly, the mCherry/sfGFP ratio of Pxa1-tFT in WT was corrected for auto fluorescence. Using the ratios obtained on day one, two and three a Z- score for each day was calculated by the formula. A Z-score indicates how many standard deviations a value is from the mean of all values. Z-score can be calculated from the formula:  $Z = (X - \mu) / \sigma$ . In the formula, Z is the Z-score, X is the value of the element,  $\mu$  is the population mean, and  $\sigma$  is the standard deviation. A negative Z-score indicates that the value of the element is below average while positive Z-score indicates the value is above average. To identify UPS mutants which potentially increased the stability of Pxa1-tFT, Z-score (Z) was calculated using the formula

$$Z = \frac{\text{mCherry/sfGFP ratio in a UPS mutant (X)} - \text{mean mCherry/sfGFP ratio in WT and UPS mutants } (\mu)}{\text{Standard deviation of mCherry/sfGFP ratio in WT and UPS mutants } (\sigma)}$$

A strain (UPS mutant) with a Z-score of 0 indicates that Pxa1-tFT stability is similar to the WT as well to the population mean (WT and UPS mutants). While, the mutants with Z-score of 1.0 and 2.0 indicates that the mCherry/sfGFP ratio in a corresponding mutant is different from the WT and population mean by 1.0 and 2.0 standard deviations. Hence, mutant stains displaying a Z-score >0 indicate enhanced Pxa1-tFT stability. UPS mutants with an increase in Z-score >1.0 on two of the three days tested were considered as potential candidates that significantly increased Pxa1-tFT stability. The heat map generated using the Z-scores (obtained from mCherry/sfGFP ratio of Pxa1-tFT in UPS mutants and the WT) is presented in Figure 2D.

#### *Fluorescence microscopy*

All images were captured at room temperature using an inverted microscope (Axio Scope A1, 100×1.30 NA Plan-Neofluar objective, Carl Zeiss), Micro-Manager software and a digital camera (CoolSNAP HQ<sup>2</sup>; Photometrics). For wide field microscopy, GFP fluorescence was visualized with a 470/440-nm band pass excitation filter, a 495-nm dichromatic mirror, and 525/50-nm band pass emission filter. mCherry fluorescence was visualized with a 587/25-nm band pass excitation filter, a 605-nm dichromatic mirror, and 647/70-nm band pass emission filter.

For co-localization analysis, cells were pre-grown on YM2 medium containing glucose, transferred to YNO-glucose (low fluorescence) medium and grown until an OD<sub>600</sub> of 1.5 after which fluorescence microscopy images were captured. For CHX chase analysis, cells grown in the same way as indicated above were treated with cycloheximide (CHX) and images were taken from cells grown on oleate/glucose at indicated time points (mins) after CHX treatment (Figure 2B). The acquired images were processed using Image J software (<https://imagej.nih.gov/ij/>) with optimal settings: mGFP (200, 500), mKate2 (200, 600) and DsRed (200, 500). For co-localization analysis in WT, *pex2*, *pex4* and *pex5* cells expressing Pxa1<sup>MUT</sup>-mGFP and Pex3-mKate2 (Figure 5C), images were processed using optimal settings: mGFP (200,

800) and mKate2 (200, 600). For quantifying the co-localization of Pxa1-mGFP or Pxa1<sup>MUT</sup>-mGFP in cells expressing peroxisomal markers (Pex3-mKate2 or DsRed-SKL) (Figure 1, 2, 6 and S1), a line was drawn along GFP and mKate2/ DsRed-SKL spots using ImageJ and the intensity was measured. Using this data, normalized fluorescent intensity of green and red spots were calculated and plotted against the distance of the line (from the beginning to the end).

For quantification of the Pex3-mKate2 and Pxa1-mGFP or Pxa1<sup>MUT</sup>-mGFP fluorescence intensities in CHX treated cells (Figure 2C), a rectangular area was drawn using ImageJ to envelope the region containing the mGFP/mKate2 spot and pixel intensity inside the area was measured. Since the cells expressing Pxa1<sup>MUT</sup>-mGFP contain very few mGFP positive spots at the later time points of CHX treatment, the rectangular area selected contained the peroxisomal marker or Pex3-mKate2 spots and the corresponding mGFP intensity was measured. The maximum fluorescence intensity of mGFP measured on peroxisomes was corrected for the background intensity and a box plot was made using Microsoft Excel. The box represents values from the 25 percentile to the 75 percentile; the horizontal line through the box represents the median value. Whiskers indicate maximum and minimum values. The mKate2 intensity was calculated and displayed in a similar way (Figure 2C). To calculate the mGFP/mKate2 intensity ratio, the maximum intensity of Pxa1-mGFP or Pxa1<sup>MUT</sup>-mGFP, obtained at different time points after CHX treatment, was divided by the corresponding maximum intensity of Pex3-mKate2 in each cell. The dataset was subjected to the two-tail t-test. \* represents P-values < 0.05, \*\* represents P-values < 0.01 and \*\*\* represents P-values < 0.001.

#### *Immunoprecipitation assay*

Immunoprecipitation was performed on cells grown on YNO-glucose medium for 10hrs and incubated with proteasome inhibitors (MG132 and Bortezomib) for 90 mins. Around 14 OD units of each strain were harvested by centrifugation. Immunoprecipitation using GFP-Trap® \_M beads was performed according to manufacturer's protocol (Chromotek) with slight modifications. Cells were washed once with 1 mL cold lysis or RIPA buffer (50 mM Tris/Cl pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100 and 0.5% Deoxycholate) and resuspended in 0.75 mL of lysis buffer containing 2.5 µg/mL leupeptin and 1 mM PMSF (added just prior to use). Yeast cells were then lysed using glass beads (~ 30 mins) and samples were centrifuged at 8000 rpm at 4°C for 10 mins to remove cellular debris and unbroken cells. A fraction of supernatant (Load fraction) was collected and stored for SDS-PAGE analysis. The remaining supernatant fractions were then incubated with 30 µl GFP-Trap® \_M beads (Chromotek) for 2 hrs at 4°C under constant mixing. The beads were magnetically separated until the supernatant was clear. The supernatant was discarded and beads were washed five times using 500 µl ice cold wash buffer (50 mM Tris/Cl pH 7.5, 150 mM NaCl and 2 mM EDTA). The GFP-Trap® \_M beads were then resuspended in 60 µl 4x SDS-Sample buffer and boiled for 10 minutes at 95°C. Finally, the beads were separated magnetically and the supernatant (Elute fraction) was collected. The load and elute fractions were subjected to SDS-PAGE and immunoblotting with antibodies against GFP and Myc tagged epitope.

#### *β- Oxidation assay*

Yeast strains were grown on glucose medium containing 5 g/L D glucose, and 6.7 g/L YNB. When required; histidine, leucine, uracil, or methionine was added. To induce peroxisome proliferation cells were grown for at least 24 hours on 5 g/L glucose medium, and then transferred to YPO medium (1.07 g/L oleate, 2.16 g/L Tween-80, 5 g/L peptone, 3 g/L yeast extract, 25 mM potassium phosphate buffer (pH=6)). Cells were grown overnight in YPO medium to induce  $\beta$ -oxidation.  $\beta$ -Oxidation assay in intact cells were performed as described previously by [80] with slight modifications. The  $\beta$ -oxidation capacity was measured in 50 mM MES, pH 6.0 and 9 g/L NaCl supplemented with 10  $\mu$ M  $1\text{-}^{14}\text{C}$ -oleate. Subsequently,  $^{14}\text{C}$ -CO<sub>2</sub> was trapped with 2 M NaOH and used to quantify the rate of fatty acid oxidation. Results are presented as percentages relative to the rate of oxidation of wild-type cells expressing Pxa1-mGFP (set to 100). The data presented are from four independent experiments and significance is calculated using two-tailed student's t test. \* represents P-values < 0.05, \*\* represents P-values < 0.01, and \*\*\* represents P-values < 0.001.

### Acknowledgments

The authors thank Alwin Slagter for assistance in strain construction, Daniel Kirrmaier for help with constructing the 'UPS library', Arjen Krikken for advice with processing of fluorescence microscopy images and Peter van Haastert and Maarten Linskens for critically reading the manuscript. This work was funded by a VIDI Fellowship (723.013.004) from the Netherlands Organisation for Scientific Research (NWO), awarded to CW. The visit of SD to the Knop lab was supported from the collaborative research centre grant SFB1036 from the German Research foundation.

### Author's Contributions

CW conceived and supervised the project, with input from EH, SK and MK. CW, SD, MM, CVR and XC designed the experiments. SD and CW analysed the data with the help from other authors. SD performed biochemical and fluorescence microscopy experiments with the support from XC. SD and MM performed tFT screening experiments. CVR performed  $\beta$ -oxidation experiment. EH was involved in plasmid construction, SD and CW wrote the manuscript with the contribution from all the authors.

### Conflict of interest

The authors declare no conflict of interest

### References

- [1] Gabaldon T. Peroxisome diversity and evolution. *Philos Trans R Soc Lond B Biol Sci.* 2010;365:765-73.
- [2] Smith JJ, Aitchison JD. Peroxisomes take shape. *Nat Rev Mol Cell Biol.* 2013;14:803-17.
- [3] Kemp S, Huffnagel IC, Linthorst GE, Wanders RJ, Engelen M. Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history. *Nature reviews Endocrinology.* 2016;12:606-15.
- [4] Nuttall JM, Motley A, Hetteema EH. Peroxisome biogenesis: recent advances. *Curr Opin Cell Biol.* 2011;23:421-6.
- [5] Mayerhofer PU. Targeting and insertion of peroxisomal membrane proteins: ER trafficking versus direct delivery to peroxisomes. *Biochim Biophys Acta.* 2016;1863:870-80.

- [6] Fang Y, Morrell JC, Jones JM, Gould SJ. PEX3 functions as a PEX19 docking factor in the import of class I peroxisomal membrane proteins. *J Cell Biol.* 2004;164:863-75.
- [7] Williams C, Opalinski L, Landgraf C, Costello J, Schrader M, Krikken AM, et al. The membrane remodeling protein Pex11p activates the GTPase Dnm1p during peroxisomal fission. *Proceedings of the National Academy of Sciences.* 2015;112:6377-82.
- [8] van Roermund CW, Ijlst L, Majczak W, Waterham HR, Folkerts H, Wanders RJ, et al. Peroxisomal fatty acid uptake mechanism in *Saccharomyces cerevisiae*. *J Biol Chem.* 2012;287:20144-53.
- [9] Chen X, Devarajan S, Danda N, Williams C. Insights into the Role of the Peroxisomal Ubiquitination Machinery in Pex13p Degradation in the Yeast *Hansenula polymorpha*. *J Mol Biol.* 2018;430:1545-58.
- [10] Williams C, van der Klei IJ. Pexophagy-linked degradation of the peroxisomal membrane protein Pex3p involves the ubiquitin-proteasome system. *Biochem Biophys Res Commun.* 2013;438:395-401.
- [11] Bett JS. Proteostasis regulation by the ubiquitin system. *Essays in biochemistry.* 2016;60:143-51.
- [12] Ye YH, Rape M. Building ubiquitin chains: E2 enzymes at work. *Nat Rev Mol Cell Bio.* 2009;10:755-64.
- [13] Schulman BA, Harper JW. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. *Nat Rev Mol Cell Bio.* 2009;10:319-31.
- [14] Metzger MB, Weissman AM. Working on a chain: E3s ganging up for ubiquitylation. *Nat Cell Biol.* 2010;12:1124-6.
- [15] Weber J, Polo S, Maspero E. HECT E3 Ligases: A Tale With Multiple Facets. *Frontiers in physiology.* 2019;10.
- [16] Metzger MB, Hristova VA, Weissman AM. HECT and RING finger families of E3 ubiquitin ligases at a glance. *Journal of Cell Science.* 2012;125:531-7.
- [17] Metzger MB, Pruneda JN, Klevit RE, Weissman AM. RING-type E3 ligases: Master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. *Bba-Mol Cell Res.* 2014;1843:47-60.
- [18] Deshaies RJ, Joazeiro CAP. RING Domain E3 Ubiquitin Ligases. *Annual Review of Biochemistry.* 2009;78:399-434.
- [19] Wenzel DM, Lissounov A, Brzovic PS, Klevit RE. UBC7 reactivity profile reveals parkin and HHARI to be RING/HECT hybrids. *Nature.* 2011;474:105-U36.
- [20] Dove KK, Stieglitz B, Duncan ED, Rittinger K, Klevit RE. Molecular insights into RBR E3 ligase ubiquitin transfer mechanisms. *Embo Reports.* 2016;17:1221-35.
- [21] Schrader M, Fahimi HD. Peroxisomes and oxidative stress. *Biochim Biophys Acta.* 2006;1763:1755-66.
- [22] Costa V, Quintanilha A, Moradas-Ferreira P. Protein oxidation, repair mechanisms and proteolysis in *Saccharomyces cerevisiae*. *IUBMB life.* 2007;59:293-8.
- [23] Shani N, Sapag A, Watkins PA, Valle D. An *S. cerevisiae* peroxisomal transporter, orthologous to the human adrenoleukodystrophy protein, appears to be a heterodimer of two half ABC transporters: Pxa1p and Pxa2p. *Ann N Y Acad Sci.* 1996;804:770-2.
- [24] Hettema EH, van Roermund CW, Distel B, van den Berg M, Vilela C, Rodrigues-Pousada C, et al. The ABC transporter proteins Pat1 and Pat2 are required for import of long-chain fatty acids into peroxisomes of *Saccharomyces cerevisiae*. *Embo J.* 1996;15:3813-22.
- [25] Shani N, Watkins PA, Valle D. PXA1, a possible *Saccharomyces cerevisiae* ortholog of the human adrenoleukodystrophy gene. *Proc Natl Acad Sci U S A.* 1995;92:6012-6.
- [26] Engelen M, Kemp S, Poll-The BT. X-linked adrenoleukodystrophy: pathogenesis and treatment. *Current neurology and neuroscience reports.* 2014;14:486.
- [27] Morita M, Matsumoto S, Sato A, Inoue K, Kostsin DG, Yamazaki K, et al. Stability of the ABCD1 Protein with a Missense Mutation: A Novel Approach to Finding Therapeutic Compounds for X-Linked Adrenoleukodystrophy. *JIMD reports.* 2019;44:23-31.
- [28] Zhang X, De Marcos Lousa C, Schutte-Lensink N, Ofman R, Wanders RJ, Baldwin SA, et al. Conservation of targeting but divergence in function and quality control of peroxisomal ABC transporters: an analysis using cross-kingdom expression. *Biochem J.* 2011;436:547-57.

- [29] Yamada T, Shinnoh N, Kobayashi T. Protease inhibitors suppress the degradation of mutant adrenoleukodystrophy proteins but do not correct impairment of very long chain fatty acid metabolism in adrenoleukodystrophy fibroblasts. *Neurochem Res.* 1997;22:233-7.
- [30] Takahashi N, Morita M, Maeda T, Harayama Y, Shimozawa N, Suzuki Y, et al. Adrenoleukodystrophy: subcellular localization and degradation of adrenoleukodystrophy protein (ALDP/ABCD1) with naturally occurring missense mutations. *Journal of neurochemistry.* 2007;101:1632-43.
- [31] Feigenbaum V, Lombard-Platet G, Guidoux S, Sarde CO, Mandel JL, Aubourg P. Mutational and protein analysis of patients and heterozygous women with X-linked adrenoleukodystrophy. *Am J Hum Genet.* 1996;58:1135-44.
- [32] Roerig P, Mayerhofer P, Holzinger A, Gartner J. Characterization and functional analysis of the nucleotide binding fold in human peroxisomal ATP binding cassette transporters. *FEBS Lett.* 2001;492:66-72.
- [33] Gurvitz A, Rottensteiner H. The biochemistry of oleate induction: transcriptional upregulation and peroxisome proliferation. *Biochim Biophys Acta.* 2006;1763:1392-402.
- [34] Karpichev IV, Small GM. Global regulatory functions of Oaf1p and Pip2p (Oaf2p), transcription factors that regulate genes encoding peroxisomal proteins in *Saccharomyces cerevisiae*. *Mol Cell Biol.* 1998;18:6560-70.
- [35] Smith JJ, Marelli M, Christmas RH, Vizeacoumar FJ, Dilworth DJ, Ideker T, et al. Transcriptome profiling to identify genes involved in peroxisome assembly and function. *J Cell Biol.* 2002;158:259-71.
- [36] Golin J, Ambudkar SV, May L. The yeast Pdr5p multidrug transporter: How does it recognize so many substrates? *Biochemical and Biophysical Research Communications.* 2007;356:1-5.
- [37] Fleming JA, Lightcap ES, Sadis S, Thoroddsen V, Bulawa CE, Blackman RK. Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341. *Proc Natl Acad Sci U S A.* 2002;99:1461-6.
- [38] Dederer V, Khmelinskii A, Huhn AG, Okreglak V, Knop M, Lemberg MK. Cooperation of mitochondrial and ER factors in quality control of tail-anchored proteins. *eLife.* 2019;8.
- [39] Hanada T, Noda NN, Satomi Y, Ichimura Y, Fujioka Y, Takao T, et al. The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy. *J Biol Chem.* 2007;282:37298-302.
- [40] Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the polyubiquitin proteolytic signal. *EMBO J.* 2000;19:94-102.
- [41] Khmelinskii A, Keller PJ, Bartosik A, Meurer M, Barry JD, Mardin BR, et al. Tandem fluorescent protein timers for in vivo analysis of protein dynamics. *Nature biotechnology.* 2012;30:708-14.
- [42] Khmelinskii A, Meurer M, Ho CT, Besenbeck B, Fuller J, Lemberg MK, et al. Incomplete proteasomal degradation of green fluorescent proteins in the context of tandem fluorescent protein timers. *Mol Biol Cell.* 2016;27:360-70.
- [43] Tong AH, Boone C. Synthetic genetic array analysis in *Saccharomyces cerevisiae*. *Methods Mol Biol.* 2006;313:171-92.
- [44] Schuldiner M, Collins SR, Thompson NJ, Denic V, Bhamidipati A, Punna T, et al. Exploration of the function and organization of the yeast early secretory pathway through an epistatic miniarray profile. *Cell.* 2005;123:507-19.
- [45] Agne B, Meindl NM, Niederhoff K, Einwachter H, Rehling P, Sickmann A, et al. Pex8p: an intraperoxisomal organizer of the peroxisomal import machinery. *Mol Cell.* 2003;11:635-46.
- [46] Sargent G, van Zutphen T, Shatseva T, Zhang L, Di Giovanni V, Bandsma R, et al. PEX2 is the E3 ubiquitin ligase required for pexophagy during starvation. *J Cell Biol.* 2016;214:677-90.
- [47] Burkhart SE, Kao YT, Bartel B. Peroxisomal ubiquitin-protein ligases peroxin2 and peroxin10 have distinct but synergistic roles in matrix protein import and peroxin5 retrotranslocation in *Arabidopsis*. *Plant Physiol.* 2014;166:1329-44.
- [48] Van der Leij I, Franse MM, Elgersma Y, Distel B, Tabak HF. PAS10 is a tetratricopeptide-repeat protein that is essential for the import of most matrix proteins into peroxisomes of *Saccharomyces cerevisiae*. *Proc Natl Acad Sci U S A.* 1993;90:11782-6.

- [49] Theodoraki MA, Nillegoda NB, Saini J, Caplan AJ. A network of ubiquitin ligases is important for the dynamics of misfolded protein aggregates in yeast. *J Biol Chem*. 2012;287:23911-22.
- [50] Kemp S, Pujol A, Waterham HR, van Geel BM, Boehm CD, Raymond GV, et al. ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. *Hum Mutat*. 2001;18:499-515.
- [51] Walker JE, Saraste M, Runswick MJ, Gay NJ. Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. *Embo J*. 1982;1:945-51.
- [52] Byeon L, Shi Z, Tsai MD. Mechanism of adenylate kinase. The "essential lysine" helps to orient the phosphates and the active site residues to proper conformations. *Biochemistry*. 1995;34:3172-82.
- [53] Schneider E, Wilken S, Schmid R. Nucleotide-induced conformational changes of MalK, a bacterial ATP binding cassette transporter protein. *J Biol Chem*. 1994;269:20456-61.
- [54] Zoghbi ME, Altenberg GA. ATP binding to two sites is necessary for dimerization of nucleotide-binding domains of ABC proteins. *Biochem Biophys Res Commun*. 2014;443:97-102.
- [55] Shani N, Valle D. A *Saccharomyces cerevisiae* homolog of the human adrenoleukodystrophy transporter is a heterodimer of two half ATP-binding cassette transporters. *Proc Natl Acad Sci U S A*. 1996;93:11901-6.
- [56] Dang Y, Siew LM, Zheng YH. APOBEC3G is degraded by the proteasomal pathway in a vif-dependent manner without being polyubiquitylated. *Journal of Biological Chemistry*. 2008;283:13124-31.
- [57] Prakash S, Inobe T, Hatch AJ, Matouschek A. Substrate selection by the proteasome during degradation of protein complexes. *Nature chemical biology*. 2009;5:29-36.
- [58] Gonzalez SL, Stremlau M, He X, Basile JR, Munger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. *Journal of Virology*. 2001;75:7583-91.
- [59] Berezutskaya E, Bagchi S. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. *Journal of Biological Chemistry*. 1997;272:30135-40.
- [60] Hwang CS, Shemorry A, Varshavsky A. Two proteolytic pathways regulate DNA repair by cotargeting the Mgt1 alkylguanine transferase. *Proc Natl Acad Sci U S A*. 2009;106:2142-7.
- [61] Winklhofer KF, Tatzelt J, Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. *EMBO Journal*. 2008;27:336-49.
- [62] Gibson JS, Ellory JC. Membrane transport in sickle cell disease. *Blood cells, molecules & diseases*. 2002;28:303-14.
- [63] Dobson CM. Principles of protein folding, misfolding and aggregation. *Semin Cell Dev Biol*. 2004;15:3-16.
- [64] Fredrickson EK, Gardner RG. Selective destruction of abnormal proteins by ubiquitin-mediated protein quality control degradation. *Semin Cell Dev Biol*. 2012;23:530-7.
- [65] Luciani A, Vilella VR, Esposito S, Brunetti-Pierri N, Medina D, Settembre C, et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. *Nature Cell Biology*. 2010;12:863-75.
- [66] Du K, Karp PH, Ackerley C, Zabner J, Keshavjee S, Cutz E, et al. Aggregates of mutant CFTR fragments in airway epithelial cells of CF lungs: New pathologic observations. *J Cyst Fibros*. 2015;14:182-93.
- [67] Ward CL, Omura S, Kopito RR. Degradation of Cfr by the Ubiquitin-Proteasome Pathway. *Cell*. 1995;83:121-7.
- [68] Thomas PJ, Ko YH, Pedersen PL. Altered Protein Folding May Be the Molecular-Basis of Most Cases of Cystic-Fibrosis. *FEBS Letters*. 1992;312:7-9.
- [69] Zhang WQ, Fujii N, Naren AP. Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas. *Future Med Chem*. 2012;4:329-45.
- [70] Park Y, Yoon SK, Yoon JB. The HECT Domain of TRIP12 Ubiquitinates Substrates of the Ubiquitin Fusion Degradation Pathway. *Journal of Biological Chemistry*. 2009;284:1540-9.

- [71] Hanoun N, Fritsch S, Gayet O, Gigoux V, Cordelier P, Dusetti N, et al. The E3 Ubiquitin Ligase Thyroid Hormone Receptor-interacting Protein 12 Targets Pancreas Transcription Factor 1a for Proteasomal Degradation. *Journal of Biological Chemistry*. 2014;289:35593-604.
- [72] Larrieu D, Brunet M, Vargas C, Hanoun N, Ligat L, Dagnon L, et al. The E3 ubiquitin ligase TRIP12 participates in cell cycle progression and chromosome stability. *Scientific reports*. 2020;10.
- [73] Kajiro M, Tsuchiya M, Kawabe Y, Furumai R, Iwasaki N, Hayashi Y, et al. The E3 Ubiquitin Ligase Activity of Trip12 Is Essential for Mouse Embryogenesis. *Plos One*. 2011;6.
- [74] Knop M, Siegers K, Pereira G, Zachariae W, Winsor B, Nasmyth K, et al. Epitope tagging of yeast genes using a PCR-based strategy: more tags and improved practical routines. *Yeast*. 1999;15:963-72.
- [75] Baerends RJ, Faber KN, Kram AM, Kiel JA, van der Klei IJ, Veenhuis M. A stretch of positively charged amino acids at the N terminus of Hansenula polymorpha Pex3p is involved in incorporation of the protein into the peroxisomal membrane. *J Biol Chem*. 2000;275:9986-95.
- [76] Khmelinskii A, Meurer M, Duishoev N, Delhomme N, Knop M. Seamless gene tagging by endonuclease-driven homologous recombination. *PLoS One*. 2011;6:e23794.
- [77] Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, Andre B, et al. Functional characterization of the *S. cerevisiae* genome by gene deletion and parallel analysis. *Science*. 1999;285:901-6.
- [78] Li Z, Vizeacoumar FJ, Bahr S, Li J, Warringer J, Vizeacoumar FS, et al. Systematic exploration of essential yeast gene function with temperature-sensitive mutants. *Nature biotechnology*. 2011;29:361-7.
- [79] Baryshnikova A, Costanzo M, Dixon S, Vizeacoumar FJ, Myers CL, Andrews B, et al. Synthetic genetic array (SGA) analysis in *Saccharomyces cerevisiae* and *Schizosaccharomyces pombe*. *Methods Enzymol*. 2010;470:145-79.
- [80] van Roermund CW, Visser WF, Ijlst L, van Cruchten A, Boek M, Kulik W, et al. The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. *Faseb J*. 2008;22:4201-8.
- [81] Gross LA, Baird GS, Hoffman RC, Baldridge KK, Tsien RY. The structure of the chromophore within DsRed, a red fluorescent protein from coral. *Proceedings of the National Academy of Sciences of the United States of America*. 2000;97:11990-5.

## Figure legends

### Figure 1: Pxa1<sup>MUT</sup>-mGFP targets to peroxisomes but displays reduced protein levels

- A. Pxa1-mGFP and Pxa1<sup>MUT</sup>-mGFP localization in cells co-expressing Pex3-mKate2 (row 4 and 6). Cells pre-cultivated on glucose were grown on oleate/glucose media to an OD<sub>600</sub> of 1.5 and fluorescence images were taken. Here, a WT strain lacking fluorescent markers (row 1) together with WT strains expressing only Pex3-mKate2 (row 2), Pxa1-mGFP (row 3) or Pxa1<sup>MUT</sup>-mGFP (row 5) act as controls. Blue arrows- GFP spots, yellow arrows- mKate2 spots and red arrows- background fluorescence. The line profiles (taken from the spots indicated with blue or yellow lines in images of WT.Pxa1-mGFP + Pex3-mKate2 and Pxa1<sup>MUT</sup>-mGFP + Pex3-mKate2 cells) indicate normalized fluorescent intensity along a line drawn through the peroxisomes (dotted yellow line). Scale bar: 3  $\mu$ m.
- B. Cells expressing Pxa1-mGFP or Pxa1<sup>MUT</sup>-mGFP were grown on oleate/glucose media to an OD<sub>600</sub> of 1.5, lysed and samples were subjected to SDS-PAGE and immunoblotting with antibodies against mGFP and Pyc.
- C. Bar chart displaying Pxa1-mGFP and Pxa1<sup>MUT</sup>-mGFP levels, normalized to the loading control Pyc. Protein levels in Pxa1-mGFP cells were set to 1. Values represent the mean  $\pm$  SD of three independent

experiments. Here, asterisks represent statistically significant decrease in Pxa1<sup>MUT</sup>-mGFP levels compared to Pxa1-mGFP levels. For quantification, blots in Figure S1C were used.

**Figure 2: Pxa1<sup>MUT</sup>-mGFP is rapidly degraded from peroxisomes**

- A. Cycloheximide (CHX) chase analysis on cells expressing Pxa1-mGFP and Pxa1<sup>MUT</sup>-mGFP. (Left) Cells pre-cultivated on glucose media were grown on oleate/glucose media (inducing condition) to an OD<sub>600</sub> of 1.5. After treatment with DMSO (Ctrl) or CHX, cells were grown further on inducing medium and samples were collected at the indicated time points for immunoblotting with antibodies against mGFP and Pyc. (Right) Quantification of Pxa1-mGFP and Pxa1<sup>MUT</sup>-mGFP levels after CHX addition. Protein levels were normalized to Pyc at the corresponding time point and to the protein levels at time point 0 (set to 1). Values represent the mean  $\pm$  SD of three independent experiments. For quantification, blots in Figure S1E were used.
- B. Co-localization analysis of Pxa1-mGFP (Left) and Pxa1<sup>MUT</sup>-mGFP (Right) with the peroxisomal marker Pex3-mKate2 after CHX treatment. Cells expressing Pxa1-mGFP or Pxa1<sup>MUT</sup>-mGFP together with Pex3-mKate2 were grown on oleate/glucose media to an OD<sub>600</sub> of 1.5 and treated with CHX. Fluorescence images were taken from cells grown on oleate/glucose media at the indicated time points (mins) after CHX addition. Blue arrows- GFP spots, yellow arrows- mKate2 spots and red arrows- background fluorescence. Scale bar: 3  $\mu$ m. Line profiles were generated as described in Figure 1.
- C. Box plot quantification of mGFP and mKate2 fluorescence intensity at the peroxisomal membrane in WT cells producing Pex3-mKate2 and Pxa1-mGFP (Left) or Pxa1<sup>MUT</sup>-mGFP (Right) after CHX treatment. Fluorescence intensities were measured in cells (n=40) using ImageJ as described in the materials and methods section. The box represents intensity values from the 25<sup>th</sup> percentile to the 75<sup>th</sup> percentile. The orange area represents intensity values from the 25<sup>th</sup> -50<sup>th</sup> percentile and the grey area represents intensity values from the 50<sup>th</sup> -75<sup>th</sup> percentile. Whiskers indicate maximum and minimum values.
- D. Average ratio  $\pm$  SD per cell (n = 40) of mGFP to mKate intensities in WT cells producing Pex3-mKate2 and Pxa1-mGFP (Left) or Pxa1<sup>MUT</sup>-mGFP (Right). Numbers above the columns (Left) depict the p-value. Asterisks (Right) denote significance between ratios at different time points, \*\* P <0.01- statistically significant (Right) and P > 0.05- not significant (Left).

**Figure 3: Inhibiting the proteasome but not autophagy disturbs Pxa1<sup>MUT</sup>-mGFP degradation**

- A. Graph representing Pxa1<sup>MUT</sup>-mGFP levels in *pdr5* cells under proteasome inhibitor (PI) conditions. *pdr5* cells expressing Pxa1<sup>MUT</sup>-mGFP pre-cultivated on glucose were grown on oleate/glucose media for 10 h. After incubation with DMSO or proteasome inhibitors (MG132 and Bortezomib) for 90 mins, CHX was added to DMSO (represented as CHX) and PI treated cells (denoted as CHX+MG132+Bortezomib). TCA samples for western blotting were collected from cells grown on oleate/glucose media at the indicated time points after treatment with inhibitors. Protein levels were normalized to Pyc at the corresponding time point and to the protein levels at time point 0 (set to 1). Values represent the mean  $\pm$  SD of three independent experiments. For quantification, blots in Figure S1F were used.

- B. Pxa1<sup>MUT</sup>-mGFP levels in WT and *atg12* cells after CHX treatment. Cells pre-cultivated on glucose were grown on oleate/glucose media to an OD<sub>600</sub> of 1.5 and treated with CHX. TCA samples were collected from cells grown on oleate/glucose at the indicated time points after CHX treatment and probed with western blotting. Protein levels were normalized to Pyc at the corresponding time point and to the protein levels at time point 0 (set to 1). For quantification, blots in Figure S1G were used.
- C. Quantification of Pxa1<sup>MUT</sup>-mGFP levels in WT cells and cells expressing Myc-tagged ubiquitin (Ub) or ubiquitin mutant (Ub<sup>K48R</sup>) after treatment with CHX. The experiment and quantification of levels were performed as mentioned in Figure 3B. Values represent the mean ± SD of three independent experiments. For quantification, blots in Figure S1G were used.
- D. Immunoprecipitation performed using anti-GFP antibodies on lysates from *pdr5* cells, *pdr5*.Pxa1<sup>MUT</sup>-mGFP cells, *pdr5*.Pxa1<sup>MUT</sup>-mGFP/MycUb cells and *pdr5*.MycUb cells. Cells were pre-cultivated on glucose, transferred to oleate/glucose media for 10 hrs and incubated with proteasome inhibitors (MG132 and Bortezomib) for 90 mins. Pxa1<sup>MUT</sup>-mGFP was immunoprecipitated under native conditions using GFP-trap magnetic beads. Load and elute fractions were subjected to immunoblotting with antibodies against the Myc-tag (to detect Myc-ubiquitin) or the GFP-tag (to detect Pxa1<sup>MUT</sup>-mGFP).

**Figure 4: Identifying factors involved in Pxa1<sup>MUT</sup>-tFT degradation by tandem fluorescent timer**

- A. Schematic representation of the Pxa1-tandem fluorescent timer (tFT) fusion. Pxa1p is fused to two fluorescent proteins with different maturation kinetics: rapidly maturing sfGFP and slow maturing mCherry. The fluorescent intensity ratio of mCherry to sfGFP provides information of Pxa1p stability.
- B. WT cells together with cells expressing Pxa1-mGFP, Pxa1-tFT or Pxa1<sup>MUT</sup>-mGFP were initially grown on glucose, shifted to oleate/glucose media and grown until an OD<sub>600</sub> of 1.5. After lysis, samples were probed by immunoblotting with antibodies against mGFP and Pyc. \*denotes a shorter, mCherry-sfGFP product resulting from mCherry hydrolysis during TCA treatment [42, 81] and \*\* denotes a tFT fragment produced by incomplete proteasomal processing [42].
- C. The stability of tFT tagged Pxa1p and Pex11p was assayed using CHX chase analysis. Cells pre-cultivated on glucose were grown on oleate/glucose media an OD<sub>600</sub> 1.5. After treatment with CHX, cells were further grown on oleate/glucose media and samples collected at the indicated points were subjected for western blotting. Protein levels obtained at each time point were normalized to Pyc at the corresponding time point and to the protein levels at time point 0 (set to 1). Values represent the mean ± SD of three independent experiments. For quantification, blots in Figure S1H were used.
- D. Screen for components involved in Pxa1-tFT stability. WT and mutant cells expressing Pxa1-tFT were grown on oleate/glucose plates and fluorescent intensities were measured. The resulting mCherry/sfGFP ratio on the indicated days (1-3) were used to calculate the Z-score (see materials and methods). Z-score colour coded from blue (decrease) to red (increase), represents changes in Pxa1-tFT stability. Mutant strains with Z-score >1.0 (indicated by \*) on two of the three days tested were defined as potentially interesting.

- E. Western blot analysis of Pxa1-tFT levels in WT, *atg12*, *pex2* and *pex4* cells grown on oleate/glucose media to an OD<sub>600</sub> of 1.5. After lysis, samples were probed by immunoblotting with antibodies against mGFP and Pyc. \*denotes a shorter, mCherry-sfGFP product resulting from mCherry hydrolysis during TCA lysate preparation [42]. The apparent discrepancy between the molecular weight of Pxa1-tFT in this panel and in Figure 4B is because samples here were run onto a 7.5% acrylamide SDS-PAGE gel while samples in 4B were loaded onto a 10% acrylamide SDS-PAGE gel, resulting in a different run profile.

**Figure 5: Pxa1<sup>MUT</sup>-mGFP degradation is inhibited in peroxisome deficient strains**

- A. Bar chart displaying Pxa1<sup>MUT</sup>-mGFP levels in WT, *pex2* and *pex4* strains (Left) and WT, *atg12* and *pex5* strains (Right). Cells pre-cultivated on glucose were grown on oleate/glucose to an OD<sub>600</sub> of ~1.5 and TCA samples were collected for western blotting. For quantification of Pxa1<sup>MUT</sup>-mGFP levels, blots in Figure S2A were used. Pxa1<sup>MUT</sup>-mGFP levels in WT were set to 1, values represent the mean ± SD of three independent experiments. Asterisks represent statistically significant increase of Pxa1<sup>MUT</sup>-mGFP levels in mutant strains compared to in WT cells. \*\* P <0.01- statistically significant and P > 0.05- not significant (NS).
- B. CHX chase of Pxa1<sup>MUT</sup>-mGFP in WT, *pex2* and *pex4* strains (Top) and WT, *atg12* and *pex5* strains (Bottom). Cells were grown on oleate/glucose media to an OD<sub>600</sub> of 1.5, treated with CHX and samples were collected from oleate/glucose grown cells at the indicated time points after CHX treatment. Protein levels were normalized to Pyc at the corresponding time point and to the protein levels at time point 0 (set to 1). Values represent the mean ± SD of three independent experiments. For quantification, blots in Figure S2B were used.
- C. Co-localization analysis of Pxa1<sup>MUT</sup>-mGFP with the peroxisomal marker Pex3-mKate2 in WT, *pex2*, *pex4* and *pex5* cells. The WT strain lacking fluorescent markers was used as control. Fluorescence images were taken from cells grown on oleate/glucose media to an OD<sub>600</sub> of 1.5. Blue arrows- GFP spots, yellow arrows- mKate2 spots and red arrows- background fluorescence. Scale bar: 3 μm

**Figure 6: Ufd4, a cytosolic E3 ligase is involved in Pxa1<sup>MUT</sup>-mGFP degradation**

- A. Pxa1<sup>MUT</sup>-mGFP levels in WT, *ufd4*, *nam7*, *ela1*, *dsk2*, *skp1*, *tul1* or *dma2* cells. TCA samples for western blotting were collected from cells pre-cultivated on glucose and grown on oleate/glucose to an OD<sub>600</sub> of ~1.5. For quantification of Pxa1<sup>MUT</sup>-mGFP levels, blots in Figure S2A were used. Pxa1<sup>MUT</sup>-mGFP levels in WT were set to 1, values represent the mean ± SD of three independent experiments. Numbers above the columns depict the p-value.
- B. Ten-fold serial dilutions of WT and *pex4* cells together with WT and *ufd4* cells producing Pxa1<sup>MUT</sup>-mGFP were spotted on oleate plates and grown at 30° C for 7 days.
- C. CHX chase of Pxa1<sup>MUT</sup>-mGFP in WT and *ufd4* strains. Cells were pre-cultivated on glucose, grown on oleate/glucose to an OD<sub>600</sub> 1.5, treated with CHX and samples were collected from oleate/glucose grown cells at the indicated time points after CHX addition. Protein levels were normalized to Pyc at the

corresponding time point and to the protein levels at time point 0 (set to 1). Values represent the mean  $\pm$  SD of three independent experiments. For quantification, blots in Figure S2B were used.

- D. Co-localization analysis of Pxa1<sup>MUT</sup>-mGFP with the peroxisomal marker Pex3-mKate2 in *ufd4* (Top panel) or WT (Bottom panel, taken from Figure 2A, for comparison) cells, after CHX treatment. Cells were grown as indicated in Figure 6C and images were taken from cells grown on oleate/glucose media at the indicated time points (mins) after CHX treatment. Blue arrows- GFP spots, yellow arrows- mKate2 spots and red arrows- background fluorescence, Scale bar: 3  $\mu$ m. Line profiles were generated as described in Figure 1. The circular structures visible in GFP images of *ufd4*.Pxa1<sup>MUT</sup>-mGFP cells (top panel) expressing Pxa1<sup>MUT</sup>-mGFP can also be seen in images of WT.Pxa1<sup>MUT</sup>-mGFP cells (Figure S1B, top lane) and likely represent large peroxisomes.

**Figure 7: Inhibiting Pxa1<sup>MUT</sup>-mGFP degradation enhances  $\beta$ -oxidation activity *in vivo*.**

- A. Bar chart displaying  $\beta$ -oxidation activity in WT and *ufd4* cells expressing Pxa1-mGFP or Pxa1<sup>MUT</sup>-mGFP.  $\beta$ -oxidation activity was measured in cells grown overnight on oleate/glucose media.  $\beta$ -oxidation in *pxa1* and *fox1* cells acts as control. The activity in WT.Pxa1-mGFP cells was taken as a reference [100%]. Values represent the mean  $\pm$  SD of four independent experiments. Numbers above the columns depict the p-value calculated to determine whether changes to  $\beta$ -oxidation activity in the different strains, are significant.
- B. Bar chart displaying Pxa1-mGFP and Pxa1<sup>MUT</sup>-mGFP levels in WT and *ufd4* cells. Pex14p levels in WT and *ufd4* cells acts as a control. Cells pre-cultivated on glucose were grown on oleate/glucose to an OD<sub>600</sub> of 1.5, cells were lysed and samples were probed by immunoblotting. For quantification, blots in Figure S2C were used. Pxa1-mGFP levels in WT.Pxa1-mGFP cells were set to 1. Similarly, Pex14 levels in WT.Pxa1-mGFP cells were used as a reference and set to 1. Values represent the mean  $\pm$  SD of three independent experiments. Numbers above the columns depict the p-value calculated to determine whether changes to Pxa1/Pxa1<sup>MUT</sup>-mGFP or Pex14p levels in the different strains, when compared to the corresponding WT strain, are significant.

## Tables

**Table 1.** Yeast strains used in this study

Strain	Description [genotype]	Reference
BY4741	<i>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0</i>	[1] (Knop lab)
BJ1991	<i>MATa, leu2, trp1, ura3-251, prb1-1122, pep4-3, gal2</i>	[2]
yMaM330 [Wild type- WT]	<i>MATalpha his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 can1Δ::STE2pr-spHIS5 lyp1Δ::STE3pr-LEU2 leu2Δ::GAL1pr- I-SCEI-natNT2</i>	[1] (Knop lab)
WT.PEX3-mKate2	<i>yMaM330, PEX3::mKate2-hphMX</i>	This study (Figure 1)
WT.PXA1-mGFP	<i>yMaM330, PXA1::mGFP-bleMX6</i>	This study (Figure 1, 2, 4, 7, S1 and S2)
WT.PXA1 <sup>MUT</sup> -mGFP	<i>yMaM330, PXA1G650S/K651R::mGFP-bleMX6</i>	This study (Figure 1, 2, 3, 4, 5, 6, 7, S1 and S2)
WT. PXA1 <sup>MUT</sup> -mGFP + PEX3-mKate2	<i>yMaM330, WT. PXA1<sup>MUT</sup>-mGFP + PEX3::mKate2-hphMX</i>	This study (Figure 1)
WT. PXA1-mGFP + PEX3-mKate2	<i>yMaM330, WT. PXA1-mGFP + PEX3::mKate2-hphMX</i>	This study (Figure 1 and Figure 2)
WT. PXA1 <sup>MUT</sup> -mGFP + DsRed-SKL	<i>yMaM330, WT. PXA1<sup>MUT</sup>-mGFP + SKL::DsRed-hphMX</i>	This study (Figure S1)
PXA1-tFT	<i>yMaM330, PXA1::mCherry-I-Scelsite-SpCYC1term-ScURA3-I-Scelsite-mCherryΔN-sfGFP</i>	This study (Figure 4 and S1H)
PEX11-tFT	<i>yMaM330, PEX11::mCherry-I-Scelsite-SpCYC1term-ScURA3-I-Scelsite-mCherryΔN-sfGFP</i>	Knop lab (Figure 4 and S1H)
<i>UPS deletion library</i>	<i>BY4741, goi deletions::kanMX</i>	[1]
yMaM344	<i>yMaM330, ura3Δ0::mCherryΔN-I-Scelsite-SpCYC1term-ScURA3-I-Scelsite-mCherryΔN</i>	[1]
<i>atg12</i>	<i>atg12 deletion strain, BY4741, atg12::kanMX</i>	Knop lab
<i>pex2</i>	<i>pex2 deletion strain, BY4741, pex2::kanMX</i>	Knop lab
<i>pex4</i>	<i>pex4 deletion strain, BY4741, pex4::kanMX</i>	Knop lab
<i>ufd4</i>	<i>ufd4 deletion strain, BY4741, ufd4::kanMX</i>	Knop lab
<i>pdr5</i>	<i>pdr5 deletion strain, BY4741, pdr5::kanMX</i>	Knop lab
<i>nam7</i>	<i>nam7 deletion strain, BY4741, nam7::kanMX</i>	Knop lab
<i>ela1</i>	<i>ela1 deletion strain, BY4741, ela1::kanMX</i>	Knop lab
<i>dsk2</i>	<i>dsk2 deletion strain, BY4741, dsk2::kanMX</i>	Knop lab

<i>skp2</i>	<i>skp2</i> deletion strain, BY4741, <i>skp2::kanMX</i>	Knop lab
<i>dma2</i>	<i>dma2</i> deletion strain, BY4741, <i>dma2::kanMX</i>	Knop lab
<i>tul1</i>	<i>tul1</i> deletion strain, BY4741, <i>tul1::kanMX</i>	Knop lab
<i>atg12.PXA1-tFT</i>	<i>yMaM330, PXA1-tFT + atg12::kanMX</i>	This study (Figure 4)
<i>pex2.PXA1-tFT</i>	<i>yMaM330, PXA1-tFT + pex2::kanMX</i>	This study (Figure 4)
<i>pex4.PXA1-tFT</i>	<i>yMaM330, PXA1-tFT + pex4::kanMX</i>	This study (Figure 4)
<i>pdr5.PXA1<sup>MUT</sup>-mGFP</i>	BY4741, <i>pdr5 + PXA1G650S/K651R::mGFP-bleMX6</i>	This study (Figure 2 and S1)
<i>atg12.PXA1<sup>MUT</sup>-mGFP</i>	BY4741, <i>atg12 + PXA1G650S/K651R::mGFP-bleMX6</i>	This study (Figure 2, 4, S1 and S2)
<i>pex2.PXA1<sup>MUT</sup>-mGFP</i>	<i>YMaM330, WT. PXA1<sup>MUT</sup>-mGFP + pex2 deletion pex2::kanMX</i>	This study (Figure 5 and S2)
<i>pex2.PXA1<sup>MUT</sup>-mGFP + PEX3-mKate2</i>	<i>yMaM330, pex2 PXA1<sup>MUT</sup>-mGFP + PEX3::mKate2-hphMX</i>	This study (Figure 5)
<i>pex4.PXA1<sup>MUT</sup>-mGFP</i>	<i>YMaM330, WT. PXA1<sup>MUT</sup>-mGFP + pex4 deletion pex4::kanMX</i>	This study (Figure 5 and S2)
<i>pex4.PXA1<sup>MUT</sup>-mGFP + PEX3-mKate2</i>	<i>yMaM330, pex4 PXA1<sup>MUT</sup>-mGFP + PEX3::mKate2-hphMX</i>	This study (Figure 5)
<i>pex5.PXA1<sup>MUT</sup>-mGFP</i>	<i>YMaM330, WT. PXA1<sup>MUT</sup>-mGFP + pex5 deletion pex5::kanMX</i>	This study (Figure 5 and S2)
<i>pex5.PXA1<sup>MUT</sup>-mGFP + PEX3-mKate2</i>	<i>yMaM330, pex5 PXA1<sup>MUT</sup>-mGFP + PEX3::mKate2-hphMX</i>	This study (Figure 5)
<i>ufd4.PXA1<sup>MUT</sup>-mGFP</i>	BY4741, <i>ufd4 + PXA1G650S/K651R::mGFP-bleMX6</i>	This study (Figure 6, 7 and S2)
<i>ufd4.PXA1<sup>MUT</sup>-mGFP + PEX3-mKate2</i>	<i>ufd4 PXA1<sup>MUT</sup>-mGFP + PEX3::mKate2-hphMX</i>	This study (Figure 6)
<i>nam7.PXA1<sup>MUT</sup>-mGFP</i>	BY4741, <i>nam7 + PXA1G650S/K651R::mGFP-bleMX6</i>	This study (Figure 6)
<i>ela1.PXA1<sup>MUT</sup>-mGFP</i>	BY4741, <i>ela1 + PXA1G650S/K651R::mGFP-bleMX6</i>	This study (Figure 6)
<i>dsk2.PXA1<sup>MUT</sup>-mGFP</i>	BY4741, <i>dsk2 + PXA1G650S/K651R::mGFP-bleMX6</i>	This study (Figure 6)
<i>skp2.PXA1<sup>MUT</sup>-mGFP</i>	BY4741, <i>skp2 + PXA1G650S/K651R::mGFP-bleMX6</i>	This study (Figure 6)
<i>dma2.PXA1<sup>MUT</sup>-mGFP</i>	BY4741, <i>dma2 + PXA1G650S/K651R::mGFP-bleMX6</i>	This study (Figure 6)
<i>tul1.PXA1<sup>MUT</sup>-mGFP</i>	BY4741, <i>tul1 + PXA1G650S/K651R::mGFP-bleMX6</i>	This study (Figure 6)
<i>ufd4.PXA1<sup>MUT</sup>-mGFP + DsRed-SKL</i>	<i>ufd4 PXA1<sup>MUT</sup>-mGFP + SKL::DsRed-hphMX</i>	This study (Figure S1)

<i>ufd4</i> .PXA1-mGFP	<i>BY4741, ufd4 + PXA1::mGFP-bleMX6</i>	This study (Figure 7 and S2)
<i>fox1</i>	<i>BJ1991, fox1::kanMX</i>	
<i>pxa1</i>	<i>yMaM330, pxa1 deletion , pxa1::hphMX</i>	This study (Figure 7)
WT.PXA1 <sup>MUT</sup> -mGFP+MycUb <sup>K48R</sup>	<i>yMaM330, WT PXA1<sup>MUT</sup>-mGFP + P<sub>CUP1</sub>-MycUbK48R [yeast episomal plasmid, Y<sub>EP</sub>-Pcup1-MycUbK48R]</i>	This study (Figure 3 and S1)
WT.PXA1 <sup>MUT</sup> -mGFP+MycUb	<i>WT PXA1<sup>MUT</sup>-mGFP + P<sub>CUP1</sub>-MycUb [yeast episomal plasmid, Y<sub>EP</sub>-Pcup1-MycUb]</i>	This study (Figure 3 and S1)
<i>pdr5</i> + MycUb	<i>pdr5 +[yeast episomal plasmid, Y<sub>EP</sub>-Pcup1-MycUb]</i>	This study (Figure 2 and S1)
<i>pdr5</i> .PXA1 <sup>MUT</sup> -mGFP + MycUb	<i>pdr5.PXA1<sup>MUT</sup>-mGFP +[yeast episomal plasmid, Y<sub>EP</sub>-Pcup1-MycUb]</i>	This study (Figure 2 and S1)

**Table 2.** Plasmids used in this study

Plasmid	Description	Use	Reference
pGW053	YCplac111 plasmid containing <i>PXA1</i> carrying two mutations <i>G650S/K651R</i> ; <i>LEU2, Amp<sup>R</sup></i>	Amplification of C-terminal <i>PXA1</i> (with <i>G650S/K651R</i> )	This study
pHIPZ-mGFP fusinator	pHIPZ containing <i>mGFP</i> ; <i>bleMX6, Amp<sup>R</sup></i>	1. Vector for cloning 2. C-terminal <i>mGFP</i> tagging to <i>PXA1</i> ; genome integration	[3]
pHIPZ-Pxa1 <sup>MUT</sup> -mGFP	pHIPZ- <i>mGFP</i> containing C-terminal <i>PXA1</i> with two mutations <i>G650S/K651R</i> [ <i>PXA1<sup>MUT</sup></i> ]; <i>bleMX6, Amp<sup>R</sup></i>	C-terminal <i>mGFP</i> tagging to <i>PXA1<sup>MUT</sup></i> ; genome integration	This study
pHIPH-Pex14mKate2	pHIPH containing <i>mKate2</i> and C-terminal of <i>PEX14</i> ; <i>hphMX, Amp<sup>R</sup></i>	1. C-terminal <i>mKate2</i> tagging to <i>PEX3</i> ; genome integration 2. Gene disruption ( <i>pxa1</i> ) by <i>hphMX</i> marker	[4]
pFA6a- kanMX6	pFA6a plasmid containing geneticin ( <i>kanMX6</i> ) resistance	Gene disruption ( <i>atg12, pex2, pex4 and pex5</i> ) by <i>kanMX6</i>	[1]

	gene; <i>kanMX</i> , <i>Amp<sup>R</sup></i>	marker	
pMaM168	pFA6a plasmid containing tFT module ( <i>mCherry-I-Scelsite-SpCYC1term-ScURA3-I-Scelsite-mCherryΔN-sfGFP</i> ); <i>URA3</i> , <i>Amp<sup>R</sup></i>	1. C-terminal tFT tagging ; <i>PXA1-tFT</i> and <i>PEX11-tFT</i> integration into yMaM330	[1]
pRG226	Yeast episomal plasmid ( <i>Y<sub>EP</sub></i> ); <i>URA3</i> , 2μ ori	Vector for cloning	Addgene, 64529
pCGCN-FAA4	Plasmid containing <i>CUP1</i> promoter and <i>mGFP</i> ; <i>bleMX6</i> , <i>Amp<sup>R</sup></i>	Amplification of <i>CUP1</i> promoter; cloning	[3]
pRDV1	Plasmid containing <i>Myc</i> tagged ubiquitin ( <i>Ub</i> ) under control of <i>DHAS</i> promoter; <i>hphMX</i> , <i>Amp<sup>R</sup></i>	Amplification of <i>MycUb</i> ; vector for cloning	[5]
pRDV2	Plasmid containing <i>Myc</i> tagged ubiquitin mutant ( <i>UbK48R</i> ) under the control of <i>DHAS</i> promoter; <i>hphMX</i> , <i>Amp<sup>R</sup></i>	Amplification of <i>MycUbK48R</i> ; Vector for cloning	[5]
<i>Y<sub>EP</sub>-P<sub>CUP1</sub>-MycUb</i>	Yeast episomal plasmid ( <i>Y<sub>EP</sub></i> ) containing <i>CUP1</i> promoter and <i>MycUb</i> ; <i>URA3</i> , <i>Amp<sup>R</sup></i>	Integration into WT. <i>PXA1<sup>MUT</sup>-mGFP</i> strain	This study
<i>Y<sub>EP</sub>-P<sub>CUP1</sub>-MycUbK48R</i>	Yeast episomal plasmid ( <i>Y<sub>EP</sub></i> ) containing <i>CUP1</i> promoter and <i>MycUbK48R</i> ; <i>URA3</i> , <i>Amp<sup>R</sup></i>	Integration into WT and WT. <i>PXA1<sup>MUT</sup>-mGFP</i>	This study
pHIPX7-DsRedSKL	Plasmid containing DsRed-SKL under the control of <i>TEF</i> promoter; <i>LEU2</i> , <i>Amp<sup>R</sup></i>	Vector for cloning	[6]
pHIPH7-DsRed-SKL	Plasmid containing DsRed-SKL under the control of <i>TEF</i> promoter; <i>hphMX</i> , <i>kan<sup>R</sup></i>	Vector for cloning	This study
pP <sub>TDH3</sub> -GFP-SKL	Plasmid containing GFP-SKL under the control of <i>TDH3</i> promoter; <i>LEU2</i> , <i>Amp<sup>R</sup></i>	Amplification of <i>TDH3</i> promoter; cloning	[7]
pHIPH8-DsRedSKL	Plasmid containing DsRed-SKL under the control of <i>TDH3</i> promoter, <i>hphMX</i> <i>Amp<sup>R</sup></i>	Integration into WT. <i>PXA1<sup>MUT</sup>-mGFP</i> and <i>ufd4</i> . <i>PXA1<sup>MUT</sup>-mGFP</i> strain	This study

## References

- [1] Khmelinskii A, Blaszczyk E, Pantazopoulou M, Fischer B, Omnus DJ, Le Dez G, et al. Protein quality control at the inner nuclear membrane. *Nature*. 2014;516:410-3.

- [2] van Roermund CW, Visser WF, Ijlst L, van Cruchten A, Boek M, Kulik W, et al. The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. *Faseb J.* 2008;22:4201-8.
- [3] Saraya R, Cepinska MN, Kiel JA, Veenhuis M, van der Klei IJ. A conserved function for Inp2 in peroxisome inheritance. *Biochim Biophys Acta.* 2010;1803:617-22.
- [4] Chen X, Devarajan S, Danda N, Williams C. Insights into the Role of the Peroxisomal Ubiquitination Machinery in Pex13p Degradation in the Yeast *Hansenula polymorpha*. *J Mol Biol.* 2018;430:1545-58.
- [5] Williams C, van der Klei IJ. Pexophagy-linked degradation of the peroxisomal membrane protein Pex3p involves the ubiquitin-proteasome system. *Biochem Biophys Res Commun.* 2013;438:395-401.
- [6] Krikken AM, Veenhuis M, van der Klei IJ. *Hansenula polymorpha* pex11 cells are affected in peroxisome retention. *FEBS J.* 2009;276:1429-39.
- [7] Kumar S, Singh R, Williams CP, van der Klei IJ. Stress exposure results in increased peroxisomal levels of yeast Pnc1 and Gpd1, which are imported via a piggy-backing mechanism. *Biochim Biophys Acta.* 2016;1863:148-56.

Journal Pre-proof

**Highlights**

- Pxa1p is a yeast peroxisomal fatty acid transporter and homologue of human ALDP.
- Mutations in ALDP cause the severe disease adrenoleukodystrophy.
- A mutant form of Pxa1p (Pxa1<sup>MUT</sup>) is degraded by the proteasome system.
- Ufd4p, a cytosolic E3 ligase, is involved in the degradation of peroxisomal Pxa1<sup>MUT</sup>.
- Inhibition of Pxa1<sup>MUT</sup> degradation partially rescues Pxa1p activity in cells.

Journal Pre-proof




**A****B****C**

Figure 1








**A****B****C****D**

Figure 2







Figure 3








**A****B****C**

Figure 5








Figure 6



**A****B**

Figure 7